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Abstract 
 
Neurovascular remodeling has been recently recognized as a promising target 
for neurologic therapies. Hopes have emerged that, by stimulating vessel growth, it 
may be possible to stabilize brain perfusion, and at the same time promote neuronal 
survival, brain plasticity, and neurologic recovery. However, the key question 
remained whether increased vessel density leads to an increase in CBF, promoting 
recovery. Many studies in the recent past have demonstrated the beneficial effects of 
therapeutic angiogenesis but had minimum benefits for patients when translated into 
the clinics. Evaluation of readouts which are less relevant clinically and usage of 
animal models which sub-optimally mimic clinical situations might be responsible for 
these discrepancies.  
 
In order to understand whether the concept of induced angiogenesis is 
feasible from a pathophysiological point of view, we evaluated the temporal profile of 
capillary formation, after treating mice with VEGF and observed that new vessel 
formation indeed results in increased CBF and preservation of the brain energy state. 
Additionally, long term VEGF therapy rendered neuroprotection and better 
preservation of the BBB integrity. Evaluation of pericyte coverage confirmed the 
production of physiologically active vessels after VEGF therapy. Due to the potent, 
pleiotropic effects, VEGF might be a promising candidate for stimulating new vessel 
formation.  
 
Hyperlipidemia affects at least half the population of stroke patients while most 
of the experimental investigations are done in young and healthy animals with an 
intact vasculature. By utilising ApoE-/- mice that exhibit exacerbated atherosclerosis 
we show that hyperlipidemia compromises new vessel formation resulting in 
decreased CBF and disruption of brain metabolism after focal cerebral ischemia. 
Additionally, hyperlipidemia increased matrix disaggregation and counteracted 
pericyte coverage by decreasing N-cadherin expression. Our data underlines the 
necessity for experimental stroke investigations utilising clinically relevant animal 
models that also mimic risk factors such as hyperlipidemia so as to minimise the 
number of study failures.  
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1 Introduction 
 
1.1 Brain and its vascular system 
  
Ever since the publication of ‘De Motu Cordis’ by William Harvey in 1628 there 
has been a growing interest into the physiological and pathological significance of the 
cardio vascular system. The cardio-vascular system comprising of the heart, arteries, 
capillaries and veins, supply the tissue with life-sustaining oxygen and other essential 
nutrients thereby maintaining homeostasis of the different body systems. The 
cardiovascular system is involved in majority of human diseases and many diseases 
are attributed to abnormalities in the system, as such. The human brain is an 
expensive organ in terms of energy usage as it uses almost one fifth of the total 
energy consumption in an adult human even though it corresponds to only 2% of the 
total body mass. As the energy reserve for the brain is only sufficient for maintaining 
the brain metabolic turnover for a few minutes, an uninterrupted vascular supply is 
warranted for a proper brain function.  
 
Stroke is one of the most prominent disease conditions, resulting from the 
abolition of blood supply through the cerebral vessels and is the major cause of adult 
disability in the United States and Europe and the second most cause of death 
worldwide. Stroke occurs due the blockage of one or more of the main arteries that 
supply blood to the brain (ischemic stroke) or by the disruption and subsequent 
leakage of a blood vessel, in the brain (haemorrhagic stroke). Stroke might lead to 
irreversible brain damage and even death if the blood supply is not restored within a 
short timeframe. The vulnerability of the brain tissue and the relatively small window 
for therapeutic interventions makes stroke one of the most intricate disease situations 
to conquer.  
 
The promotion of vascular remodeling has been recently recognized as a 
particularly promising therapeutic strategy in brain illnesses (Greenberg and Jin, 
2005; Chen and Chopp, 2006; del Zoppo and Mabuchi, 2003; Hansen et al., 2008; 
Hermann and Chopp., 2012). Hopes have emerged that by stimulating the growth of 
new vessels, it may be possible to stabilize brain perfusion, and at the same time 
promote neuronal survival, plasticity, and functional recovery, once a stroke has 
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occurred (Chen and Chopp, 2006; del Zoppo and Mabuchi, 2003; Hermann and 
Chopp., 2012). 
 
1.1.1 Physiological and pathological angiogenesis 
 
Angiogenesis is the formation of new blood vessels from pre-existing ones. 
The process of angiogenesis depends on a delicate balance between stimulators and 
inhibitors and any divergence from this balance result in pathophysiological 
consequences.  During the embryonic development blood vessels supply the tissues 
with oxygen and nutrients and in the later stages, maintain the supply to the organs 
by developing and integrating into a vascular network. In adults, however the process 
of angiogenesis is largely dormant barring conditions of wound healing, ovarian cycle 
and pregnancy. Induction of angiogenesis occurs when the balance between 
stimulators and inhibitors are tilted in favour of the former, which results from the 
induction of hypoxia in the tissues. Expression of hypoxia inducible factors in the 
tissue stimulates the production of pro-angiogenic molecules including VEGF 
(vascular endothelial growth factor) and angiopoeitins resulting in the stimulation, 
proliferation and to the formation of tubes by endothelial cells.  
 
Angiogenesis is part of the natural defence mechanism of the brain to restore 
homeostasis after an ischemic accident. Angiogenesis might also play a role in 
neurotrophic support as the neuroblasts are found to be concentrated along blood 
vessels after ischemia (Yamashita et al., 2006; Beck and Plate, 2009). Indeed, stroke 
patients with greater microvessel density in the ischemic border show longer survival 
periods (Krupinski et al., 1994, Beck and Plate, 2009).  
 
Angiogenesis is also a prominent feature of tumor growth as this provides the 
tumor tissue with nutrients and oxygen along with the removal of wastes. Tumor 
tissue release angiogenic growth factors which stimulate the outgrowth of vessels 
thereby enabling the cancerous tissue to undergo proliferation and metastasis. 
Insufficient or excessive angiogenesis is found to the common denominator for more 
than 70 diseases in humans including ischemia, many type of cancers, age-related 
blindness, cardiovascular diseases and diabetic ulcers (Folkman J et al., 2000).  
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Angiogenic therapy which stimulates the production of new blood vessels to 
restore blood supply to the starving tissues and anti-angiogenic therapy which aims 
to inhibit the production of new blood vessels by tumor tissue thereby inhibiting the 
proliferation of tumours are believed to benefit more than 500 million patients 
worldwide. 
 
 
1.1.2 Remodelling at the neurovascular unit 
 
 
Brain neurons and astrocytes critically depend on the integrity of a functional 
capillary system that supplies oxygen and energy-rich substrates to the tissue (Han 
and Suk, 2005). To safeguard this continuous supply, neurons and astrocytes 
release various angiogenic factors, such as VEGF, angiopoietins, bFGF (basic 
fibroblast growth factor), G-CSF (granulocyte colony-stimulating factor), Epo 
(erythropoietin), transforming growth factor-b, and insulin-like growth factor-1 (Jain 
and Munn, 2000; Zhang and Chopp, 2002; Park et al, 2003), which together with 
guidance molecules, namely semaphorins, ephrins, netrins, and their receptors 
(Adams and Klein, 2000; Carmeliet, 2003), induce endothelial proliferation, directed 
vessel growth, and formation of a functional vascular network. Similar to neurons and 
astrocytes, endothelial cells also release growth factors, such as brain-derived 
neurotrophic factor, nerve growth factor, and neurotrophins, which promote the 
viability of neurons, providing a sustained protection under conditions of oxygen 
deprivation (Carmeliet, 2003; Hennigan et al., 2007; Lok et al., 2007). At the same 
time, through an interaction with the receptors of these growth factors, namely 
Tropomyosin receptor kinase A (TrkA), Tropomyosin receptor kinase B (TrkB), and 
p75 neurotrophin receptor (p75NTR) (Hennigan et al., 2007), these growth factors 
promote reorganization processes in the brain, facilitating long-term potentiation and 
synaptic plasticity (Bliss and Collingridge, 1993) and promoting axon outgrowth 
through an interaction with guidance cues, such as semaphorins, ephrins, slits, and 
netrins (Bagri and Tessier-Lavigne, 2002; Dickson, 2002; Carmeliet, 2003). The 
mutual interactions between endothelial cells, neurons, and astrocytes have led to 
the concept of the neurovascular unit (Hawkins and Davis, 2005; del Zoppo and 
Mabuchi, 2003; Lok et al, 2007), upon which these cells should not be regarded as 
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separate entities but as integrated networks that need to respond to injuries in a 
coordinated, synergistic manner so that recovery becomes possible (Chopp et al, 
2008). The physiologic interactions between neurons and vessels provide insights 
into endogenous protective responses activated by the brain after an ischemic attack. 
This raises hopes that by strengthening these mechanisms, it may be possible to 
promote recovery for therapeutic purposes. 
 
 
1.1.3 Different types of blood vessel formation 
 
The major processes which result in the formation of new vessels are (a) 
vasculogenesis (b) angiogenesis, and (c) arteriogenesis (Carmeliet, 2004). 
Vasculogenesis refers to the formation of blood vessels from the blood-borne or 
tissue-residing endothelial stem cells which migrate into the site of vascularization 
and differentiate to form the vascular plexus (Semenza, 2007), a phenomenon 
largely prominent during the embryonic stage. Angiogenesis on the other hand 
corresponds to the formation of capillary branches from pre-existing vessels and is 
the major feature of physiological angiogenesis. Arteriogenesis refers to the increase 
in the luminal diameter of an artery so as to increase perfusion for the tissue at risk. 
 
The process of angiogenesis is induced by the production of hypoxia inducible 
factors stimulating the secretion of angiogenic growth factors. The presence of 
angiogenic growth factors activate the receptors present on endothelial cells resulting 
in the proliferation and migration of the endothelial cells. During the process of 
sprouting angiogenesis, the basement membrane is degraded by proteases 
produced by the activated endothelial cells allowing the cells to migrate to the 
adjacent tissue (Burri et al., 2004). The migrating cells then form sprouts, connecting 
vessels which then migrate to the site of the angiogenic stimulus. Sprouting 
angiogenesis differs from so called intussusceptive angiogenesis due to the fact that 
it results in the formation of completely new vessels (Burri et al., 2004). During 
intussusceptive angiogenesis the capillary wall of existing vessel extends into the 
lumen thereby slitting the vessels into two (Burri et al., 2004). Intussusceptive is 
prominent during the formation of embryonic vasculature as the process significantly 
increases the number of capillaries without the expense of endothelial cells.  
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1.2 Role of angiogenesis in brain ischemia 
 
 
During development, central nervous system (CNS) acquires its vasculature 
through angiogenesis rather than vasculogenesis (Greenberg and Jin, 2005). 
Invading vessels from the pia matter converge towards the ventricles during the 
process of embryogenesis and give off secondary branches that surround the 
ventricles (Greenberg and Jin, 2005) resulting in the formation of cerebro-vascular 
system. Cerebral circulation is also distinctive from the peripheral systems by the 
presence of the blood brain barrier (BBB) which controls the entry of molecules to 
and from the brain. Disruption of the BBB during cerebrovascular accidents results in 
edema formation and associated consequences in the brain. Blood vessels in the 
brain are equipped with control mechanisms responding to the changes in local 
metabolic demand by effecting changes in cerebral blood flow (CBF). The structural 
and functional integrity of the brain depends on a continuous vascular supply of 
oxygen and glucose, which once interrupted causes cessation of neuronal activity 
leading to neuronal death from apoptotic and/or necrotic mechanisms (Hossmann, 
2006). After ischemia, cerebral blood vessels in the vicinity of the stroke lesion 
sprout, enabling the brain parenchyma to a plethora of endogenous responses that 
enable successful neurological recovery (Hermann and Chopp, 2012). 
 
 
1.2.1 Angiogenic responses in the ischemic brain 
 
 
As angiogenesis forms a crucial part of the recovery process in many organ 
systems, cerebral angiogenesis has also been suggested as a natural recovery 
response of the brain after ischemia (Arai et al., 2009). Increased microvessel 
densities in the penumbra region were correlated with increased survival of human 
patients (Krupinski et al., 1993; Krupinski et al., 1994). On the other hand, worse 
prognosis was observed in patients with reduced new vessel formation after stroke 
(Allen, 1984; Granger et al., 1992; Szpak et al., 1999). The proliferation of endothelial 
cells increases exponentially after ischemia via activation of growth factors (such as 
VEGF) and their receptors. The synergistic regulation of angiogenesis promoters and 
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their receptors extends from hours to months after ischemia, suggesting the role 
played by angiogenesis in long-term neurovascular remodelling and recovery. Gene 
regulation studies in experimental stroke models have shown that endogenous 
signals for VEGF are expressed in neurons and astrocytes after focal cerebral 
ischemia (Zhang et al., 2000). Intriguingly, the receptors responsible for most of the 
angiogenic actions of VEGF (i.e vascular endothelial growth factor receptor2 
(VEGFR2) and neuropilin) are expressed in the astrocytes only in the post ischemic 
state (Hermann and Zechariah, 2009).   
 
 
1.2.2 Implications of angiogenesis for the ischemic brain 
 
 
The responses of VEGF system and its contribution to angiogenesis lead to 
the question about the benefit which the brain has from increasing its vessel density. 
There are five major concepts on this question, which are (i) hypoxia hypothesis, (ii) 
capillary recruitment hypothesis (iii) neurotropic hypothesis and (iv) neuroblast 
migration scaffold hypothesis (v) clean-up hypothesis (summarised in figure 1). 
 
 
According to the hypoxia hypothesis, ischemia-induced expression of hypoxia 
inducible factor (HIF)-1 and -2 drives the neovascularization in the infarct border 
zone via expression of VEGF, aiming to stabilize the perfusion of the tissue (Marti et 
al., 2000). Unfortunately the formation of new capillaries is slow. The density of new 
vessels starts to increase not before 48 hours after stroke (Seylaz et al., 1999; Pinard 
et al., 2000; Marti et al., 2000). VEGF delivery increases angiogenesis, but does not 
significantly change the time-line in which new capillaries are formed (Sun et al., 
2003; Wang et al., 2005). Thus, there are few reasons to assume that angiogenesis 
has relevant effects on brain hemodynamics during an acute ischemic event. 
However, the question whether angiogenesis can protect the brain against 
subsequent ischemic episodes, remains to be elucidated. 
 
 
  
 
                                          VEGF-induced angiogenesis in focal cerebral ischemia/ 8 
 
The capillary recruitment hypothesis postulates that VEGF has a second effect 
besides promoting vessel growth, i.e., the improvement of vascular perfusion by 
relaxation of the vessels. In fact VEGF delivery acutely improved cerebral blood flow 
(CBF) of ischemic tissue during the first three hours after cerebral thromboembolism, 
when applied at high doses via systemic delivery (Zhang et al., 2000). Whether this 
effect reflects a restoration of vascular reactivity, e.g., by boosting endothelial NO 
levels, as suggested by in vitro studies (Wu et al., 1996), remains to be shown. It is 
still unclear to which extent this hemodynamic improvement contributes to VEGF’s 
survival effect. In the experiments above (Zhang et al., 2000), no neuroprotective 
effect was noted after acute VEGF treatment. 
 
 According to the neurotrophic hypothesis, newly formed vessels are rich 
sources of trophic molecules that promote the survival of ischemic neurons at risk. 
Thus, vascular density is elevated not in order to enhance hemodynamics but to 
provide a microenvironment in which injured neurons are capable to survive (Chen 
and Chopp, 2006; Chopp et al., 2008). In contrast to the two preceding concepts, this 
is the first and only hypothesis that specifically relates to the brain tissue. That 
neurotrophic responses are important for tissue survival is supported by the dynamic 
responses of growth factors and their receptors, via which microvessels, neurons and 
glial cells interact with each other after ischemia. From a system biological view, the 
formation of new vessels is an energy intensive process, and it is surprising that the 
hemodynamically compromised brain chooses this strategy in order to survive. Thus, 
some open questions remain about this concept. 
 
 The neuroblast scaffold hypothesis assumes that newly formed vessels in the 
peri-infarct zone create a suitable environment for the migration, homing and 
differentiation of neuroblasts (Hermann and Chopp, 2012). Activated endothelial cells 
and vessels produces an array of trophic factors and cytokines such as stromal 
derived factor 1 (SDF-1), VEGF, and matrix metalloproteinases 2 and 9 (MMP2, 9) 
which serves as chemoattractant for neuroblast cells (Wang et al., 2006a; Chopp et 
al., 2007; Hermann and Chopp, 2012). Additionally, neuroblasts are found to be 
concentrated around blood vessels following stroke (Beck and Plate, 2009) where 
they migrate in close vicinity to vascular cells thus using blood vessels as a scaffold 
for migration in direction to the site of injury.  
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An alternative interpretation of the enhanced angiogenesis following stroke is 
the removal of dead tissue. According to the clean-up hypothesis, newly formed 
vessels allow macrophages to enter the tissue and to remove cell debris 
(Manoonkitiwongsa et al., 2001). In fact, the density of newly formed vessels closely 
correlated with that of macrophages in the ischemic brain, which supports that view 
(Manoonkitiwongsa et al., 2001). VEGF increased new vessel formation and 
macrophage infiltration in the brain (Manoonkitiwongsa et al., 2004, 2006). The 
clean-up hypothesis brings together two features of VEGF, its angiogenic and 
permeability-promoting function. As such, the main goal of newly formed vessels is 
not to provide oxygen and nutrients, but to guide inflammatory cells into tissue areas 
of damage. The question remains whether specialised vascular networks are 
required for the purpose of debris removal and about the validity of this concept in 
view of the high blood flow levels in the mammalian brain under normal, physiological 
conditions. Additionally, blood flow is much higher in the brain than in other tissues 
and the clean-up hypothesis may not only be relevant for brain tissue as such, but 
also for peripheral tissues but there are no convincing answers to this question.  
 
 
Taken together, although angiogenesis is a key feature in the remodelling of 
ischemic brain tissue, the process still remains to some extent a conundrum. There is 
no commonly accepted explanation of why new vessel formation takes place.  
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Figure 1. Five major concepts regarding the role of angiogenesis in the 
ischemic brain. According to the hypoxia hypothesis, oxygen and glucose 
deprivation induced by the occlusion of a brain-supplying artery (indicated by the 
purple coloured clot) induces vessel sprouting order to provide oxygen (indicated by 
blue balloons) and glucose (grey triangles) to ischemic neurons at risk. Unfortunately, 
the formation of new capillaries is slow. In order to overcome this limitation, VEGF 
also induces an acute increase of cerebral blood flow by dilation of blood vessels 
(indicating by bidirectional flashes in left upper Figure) according to the vascular 
recruitment hypothesis. Newly formed vessels are rich sources of trophic molecules 
(i.e., growth factors; indicated by red hexagons) that based on the neurotrophic 
hypothesis promote the survival of ischemic neurons at risk. As such, new vessel 
formation creates a microenvironment in which injured neurons are capable to 
survive. The neuroblast scaffold hypothesis suggests that newly formed vessels acts 
as a scaffold for neuroblasts (indicated in green colour in the upper right part of the 
figure) to reach the site of injury and thereby participating in the remodelling process. 
A further role of the enhanced angiogenesis is the removal of dead tissue. According 
to the clean-up hypothesis, newly formed vessels allow macrophages to enter the 
brain parenchyma and to remove cell debris (indicated in lower part of the cartoon 
that illustrates macrophages in close vicinity to a degenerating neuron and its axon).  
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1.2.3 Regulation of angiogenic growth factors after ischemia 
 
Ischemia profoundly regulates angiogenic and neuroprotective cytokines in the 
brain. The expression of VEGF and its receptor (Flk-1) increase from 1 hour post 
stroke; an effect which is known to last at least for several days (Carmichael, 2003; 
Hayashi et al 2003). Neuropilin-1, co-receptor for VEGF is also expressed along the 
same pattern as Flk-1, as the increased expression is observed 24 hours after stroke 
(Carmichael, 2003; Hayashi et al 2003). The early phase of stroke also witnesses 
increased expression of angiopoeitin-2, Beta-3 integrin and Ephrin B2 and B4 
(Carmichael, 2003; Hayashi et al 2003; Varner et al 1995).  
 
On the other hand, the expression pattern of angiopoietin-1, which reverses 
the permeability effects of ang-2 is found to increase 7 days post stroke and is 
believed to play a role in the stabilization of new born vessels by establishing pericyte 
coverage (Carmichael, 2003; Hayashi et al 2003). The expression of placental 
growth factor is observed in the chronic phase of stroke (21 days post stroke) which 
corresponds to the role played by this molecule in post ischemic vascular remodelling 
(Carmeliet, 2000; Carmichael, 2003). On the other hand, the significance of 
molecules including Epo, insulin like growth factor (IGF) and hepatocyte growth 
factor (HGF) which has proven beneficial effects in neuronal plasticity and 
remodelling (Carmichael, 2003; Hayashi et al 2003) remains less clear. 
 
 
1.3 The vascular endothelial growth factor 
 
Having been discovered in the early 1980’s (Senger et al., 1983) and being 
cloned in the late 1980’s (Keck et al., 1989; Leung et al., 1989), VEGF is known for 
its pleotrophic actions on brain cells. Tissue protection, new vessel formation and 
brain plasticity are key features underlying the neurovascular remodelling induced by 
VEGF. All three processes are closely linked, being orchestrated in a temporospatial 
way. The multifaceted effects of VEGF – promoting neuronal survival, angiogenesis 
and brain plasticity at the same time – had nourished hopes that by use of a single 
molecule it may become possible to promote neurological recovery after stroke.  
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1.3.1 VEGF isoforms and regulation upon ischemia and hypoxia 
 
 
VEGF is a pivotal regulator in angiogenesis that is markedly increased in 
ischemic brain tissues. As such, the growth factor well exemplifies how recovery 
processes are initiated and regulated in the stroke brain. In humans, the VEGF family 
consists of five homodimeric members (VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
placental growth factor [PlGF]), among which VEGF-A stimulates angiogenesis in a 
particularly powerful way (Olsson et al., 2006; Hansen et al., 2008). VEGF-A (in the 
following referred to as VEGF) exists in at least six isoforms (VEGF121, VEGF145, 
VEGF165, VEGF183, VEGF189, VEGF206), which differ in their binding affinity to VEGF 
receptors.  
 
VEGF is ubiquitously expressed in the brain under physiological conditions 
mainly by choroid plexus epithelial cells, but also by astrocytes and microglia 
(Monacci et al., 1993; Marti and Risau, 1998). In brain hypoxia and ischemia, VEGF 
expression is rapidly increased within hours in a HIF-1 and HIF-2 dependent way 
(Forsythe et al., 1996; Marti and Risau, 1998; Abumiya et al., 1999; Lennmyr et al., 
2005), and VEGF remains elevated over as long as one month after the stroke (Hai 
et al., 2003; Wang et al., 2004). As such, VEGF is not only upregulated on glial cells 
(Marti and Risau, 1998; Abumiya et al., 1999), but it is also induced on neurons 
(Marti and Risau, 1998), microvascular smooth muscle cells (Brogi et al., 1994; 
Abumiya et al., 1999), pericytes (Yonekura et al., 1999) and leukocytes (Abumiya et 
al., 1999). After stroke, VEGF expression is not restricted to ischemic areas, but also 
found in remote cortex regions (Stowe et al., 2007). Hence, additional mechanisms 
besides hypoxia might be involved in the regulation of this growth factor. 
 
Angiotensin receptor antagonism in stroke animals resulted in an increase of VEGF-
B and its receptor vascular endothelial growth factor receptor 1 (VEGFR1) leading to 
akt-phosporylation and decrease in ischemic injury (Guan et al., 2011). Vascular 
endothelial growth factor receptor 3 (VEGFR-3) which mediates actions of VEGF-C 
and VEGF-D was predominantly expressed in reactive astrocytes in the penumbra 
region after focal cerebral ischemia (Shin et al., 2010). Additionally, VEGF-C 
overexpression is able to stimulate the production of VEGFR-3-expressing NSCs and 
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neurogenesis in the SVZ without affecting angiogenesis (Calvo et al., 2011). The 
PlGF expression in cultured endothelial cells was significantly enhanced by VEGF 
stimulation and the upregulation of endogenous PlGF expression was significantly 
decreased by the inhibition of endogenous VEGF activity in vivo (Fujii et al., 2008). 
 
 
1.3.2 The VEGF receptor family 
 
VEGF binds two related receptor tyrosine kinases (RTK), VEGFR-1 (flt-1) and 
VEGFR-2 (flk-1, KDR), consisting of seven extracellular immunoglobulin-like 
domains, a transcellular domain and a consensus tyrosine kinase sequence (Shibuya 
et al., 1990; Terman et al., 1991). Besides VEGFR-1 and VEGFR-2, a third RTK, 
VEGFR-3, exists, which binds to VEGFC and VEGFD but not VEGF (Karkkainen et 
al., 2002). In addition to RTKs, a co-receptor, neuropilin-1 (NRP-1), has been 
identified (Soker et al., 1996), which is otherwise involved in axon-repulsive 
semaphorin-3a signalling (Neufeld et al., 2002), presenting VEGF165 to VEGFR-2, 
thus enhancing VEGFR-2’s signal response (Soker et al., 1998).  
 
VEGFR-2 mediates most of the mitogenic, angiogenic and permeability-
enhancing effects of VEGF (Ferrara et al., 2003; see Table 1). VEGFR-2-/- mice 
exhibit a severe lack of vasculogenesis and failure to develop blood islands, resulting 
in early death in utero (Shalaby et al., 1995). VEGFR-2 exhibits several tyrosine 
residues that are phosphorylated in response to VEGF (Roskoski, 2008) inducing a 
broad intracellular signal response involving phosphatidyl inositol-3 kinase (PI3K)/ 
Akt, Ras GTPase-activating protein, tyrosine kinase Src and Raf-mitogen activating 
protein kinase (MAPK) - extracellular regulated kinase (ERK)-1/2 pathways (Ferrara 
et al., 2003).  
 
 
Compared with VEGFR-2, VEGFR-1 less potently influences angiogenesis 
and vascular permeability. VEGFR-1 was proposed to act as a decoy receptor (Park 
et al., 1994), representing a scavenger that prevents VEGF binding to VEGFR-2 
(Roskoski, 2008). Indeed in embryonic tissues, VEGFR-1 is a negative regulator of 
new vessel growth (Fong et al., 1995). VEGFR-1’s binding affinity to VEGF is about 
an order of magnitude higher than that of VEGFR-2, while its tyrosine kinase activity 
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is an order of magnitude lower than that of VEGFR-2 (Shibuya, 2006; Roskoski, 
2008), which explains its partly antagonistic role. Being strongly expressed on 
macrophages, VEGFR-1 promotes inflammatory responses in peripheral tissues and 
perhaps atherosclerosis (Shibuya, 2006). As such, VEGFR-1’s role might vary 
between the pathophysiological contexts, in which it is active. 
 
 
 
Table 1: Expression of VEGF receptors in the healthy and ischemic brain 
 
 
Healthy brain Ischemic brain        Name Receptor type Physiologic effect 
in vivo Endo-
thelial 
cells 
Neu-
rons 
Astro-
cytes 
Endo-
thelial 
cells 
Neu-
rons 
Astro-
cytes 
VEGFR-2 VEGF 
receptor 
tyrosine 
kinase 
Mitogenic, 
angiogenic and 
permeability-
enhancing activity 
+ (+) - + + + 
VEGFR-1 Weak VEGF 
receptor 
tyrosine 
kinase 
Proinflammatory 
and 
atherosclerotic; 
ambiguous role in 
angiogenesis and 
vascular 
permeability 
(+) (+) - + + - 
Neuropilin-1 Co-receptor to 
VEGFR-2; 
receptor for 
semaphorin-
3a 
Potentiates 
VEGFR-2’s 
angiogenic and 
permeability-
promoting activity 
(+) (+) - + + + 
 
-, not expressed; (+), weak expression; +, moderate to strong expression 
 
Adopted from Hermann and Zechariah (2009) 
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1.3.3 Role of VEGF in post-ischemic angiogenesis 
 
In the process of angiogenesis, the loss of vascular integrity and degradation of the 
cell matrix are crucial initiating steps. The dilation of ischemic vessels that is evoked 
by release of nitric oxide (NO) (Distler et al., 2003) is rapidly followed by the loss of 
tight junction integrity, brought about by the phosphorylation of junctional proteins 
(Takenaga et al., 2009), which further goes along with the degradation of the basal 
lamina (del Zoppo and Mabuchi, 2003). These events are rapidly activated within 
only one to two hours after stroke, resulting in an increase in vascular permeability 
that facilitates extravasation of plasma proteins into the neighbouring tissue (Fig. 2). 
The extravasated plasma proteins provide mechanical support for migrating 
endothelial cells.  
 
With the help of supporting cells located in the perivascular space, 
extracellular matrix constituents, namely laminins, collagen type IV, fibronectin, 
heparin sulphates and heparin sulphate proteoglycans (del Zoppo and Mabuchi, 
2003) are degraded. Major effectors of this process are (i) MMPs, which already exist 
in proforms and are enzymatically activated upon stroke, (ii) plasminogen activator 
inhibitor (PAI)-1 and urokinase, which are de novo expressed along the infarct border 
on endothelial cells, astrocytes and neurons, (iii) tissue-plasminogen activator, which 
forms complexes with PAI-1 and (iv) angiopoietins, namely angiopoietin-1 and its 
natural antagonist angiopoietin-2 (see Fig. 2).  
 
The degradation of the extracellular matrix prepares the stage for growth 
factors and guidance molecules. Together with other angiogenic factors, VEGF 
induces the proliferation of endothelial cells that migrate along a gradient of 
chemotactic cues (Yancopoulos et al., 2000; Ruhrberg et al., 2002; Carmeliet, 2003). 
The highly basic isoforms VEGF189 and VEGF206 are involved in this process mainly 
as matrix-bound short distance guidance cues, whereas VEGF121 and VEGF165 are 
more diffusible growth signals acting over larger distances (Fig. 2; Houck et al., 1992; 
Park et al., 1993). Endothelial migration is supported by pericytes that release 
several angiogenic factors, including VEGF, that migrate away from vessels into the 
perivascular space, where they release proteases including MMPs and urokinase, 
guiding endothelial cells towards their targets (Dore-Duffy and LaManna, 2007). 
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While migrating through the brain matrix, endothelial cells arrange themselves 
into cell monolayers and form tube-like structures (Fig. 2). The mesenchymal cells in 
the surrounding proliferate and move to the abluminal surface of the newly formed 
vessels. As such, endothelial cells and pericytes start to interact with each other 
(Hanahan, 1997; Carmeliet, 2000; Dore-Duffy and LaManna, 2007), pericytes 
releasing angiopoietin-1 that stabilizes the new-born vessels via its receptor Tie-2 
(Fig. 2; Croll and Wiegand, 2001; Zacharek et al., 2007). The newborn vessels still 
need to build a functional BBB by formation of tight junctions between endothelial 
cells. Pericytes again control this BBB formation in an angiopoietin-1/ Tie-2 
dependent way (Fig. 2; Thurston et al., 1999; Wang et al., 2007b).  
 
It has recently been suggested that VEGF itself counteracts the maturation of 
new-born blood vessels by disrupting the pericyte coverage of the vessel sprouts 
(Fig. 2; Greenberg et al., 2008). In this study, the authors evaluated the effects of 
platelet-derived growth factor (PDGF), demonstrating that PDGF’s receptor PDGFRβ 
forms a complex with one of VEGF’s receptors, VEGFR-2, once PDGF is in place 
(Greenberg et al., 2008). Inhibition of VEGFR-2 prevented the assembly of this 
receptor complex and restored the maturation of the vessels (Greenberg et al., 
2008).  
 
Following hypoxia-ischemia, VEGF and angiopoietins are expressed in a 
temporally and spatially orchestrated fashion. As such, angiopoietin-1 is induced 
slightly later than VEGF in the peri-infarct borderzone, starting at 1-2 days post-
stroke (Croll and Wiegand, 2001). At the same time, the expression of angiopoietin-
1’s counterplayer angiopoietin-2, which may have angiogenic or anti-angiogenic 
effects depending on its microenvironment (Jones et al., 2001; Zhu et al., 2005b), 
decreases (Croll and Wiegand, 2001). The temporospatially coordinated release of 
VEGF and angiopoietins well illustrates that the right factors need to be in place at 
the right time-point so that neurological recovery may become possible. Interestingly, 
the upregulation of VEGF takes place at a time-point at which the extracellular matrix 
is degraded, whereas upregulation angiopoietin-1 and downregulation of 
angiopoietin-2 coincide with the resolution of brain edema. Hence, molecular 
processes and pathophysiological changes closely go along with each other. 
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Figure 2. Upper. Role of VEGF in post-ischemic angiogenesis. In the ischemic 
brain tissue, the loss of vascular integrity, brought about by NO, is a crucial initiating 
step, which results in the extravasation of plasma proteins into the neighbouring 
tissue. With the help of angiopoietins, namely angiopoietin-1, MMPs and tissue-
plasminogen activator, the basal membrane is degraded, which prepares the stage 
for VEGF that induces the proliferation of endothelial cells. The highly basic isoforms 
VEGF189 and VEGF206 (shown in blue and green) are involved in this process mainly 
as matrix-bound short distance guidance cues, whereas VEGF121 and VEGF165 
(shown in purple and grey) are diffusible growth signals acting over larger distances. 
Lower. While migrating through the brain matrix, endothelial cells arrange 
themselves in cell monolayers and form tube-like structures. Pericytes from the 
surrounding proliferate and arrange around the abluminal surface of the newly 
formed vessels. These pericytes release angiopoietin-1, which induces the formation 
of tight junctions via binding to Tie-2 receptor that is localized on endothelial cells. 
VEGF counteracts the maturation of new-born blood vessels by disrupting the 
pericyte coverage of the vessels (from Hermann and Zechariah, 2009).  
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1.3.4 Expression of VEGF receptors in the ischemic brain 
 
The functions of VEGF receptors are relevant not exclusively for brain microvessels 
but also for vessels in other tissues as well. In the adult brain, VEGFR-2 is found on 
newborn microvascular endothelium (Marti et al., 2000; Beck et al., 2002) that exhibit 
the capacity of proliferation and growth, and it is also weakly expressed on healthy 
neurons (Beck et al., 2002) (see Table 1). The density of VEGFR-2+ capillaries 
increases within 48 hours after stroke (Marti et al., 2000) and it is further elevated in 
the presence of VEGF (Wang et al., 2005) (Table 1). Both the level of VEGF 
expression and its cellular distribution, change in response to stroke. As such, 
VEGFR-2 more strongly appears on ischemic neurons (Jin et al., 2000; Matsuzaki et 
al., 2001; Wick et al., 2002; Beck et al., 2002; Kilic et al., 2006a) and astrocytes 
(Lennmyr et al., 1998; Kilic et al., 2006a; Choi et al., 2007) (Table 1).  
 
Observations of an altered expression have also been made for VEGFR-1, 
which exhibits weak expression on endothelial cells (Beck et al., 2002) and neurons 
(Beck et al., 2002; Choi et al., 2007) under physiologic conditions and which is 
upregulated on hypoxic-ischemic endothelial cells (Lennmyr et al., 1998; Plate et al., 
1999; Beck et al., 2002), neurons (Lennmyr et al., 1998; Matsuzaki et al., 2001; Wick 
et al., 2002) and pericytes (Levine et al., 2004; Dikov et al., 2005) during the first 
three days post-stroke (Table 1); for VEGFR-2’s coreceptor NRP-1, which is 
expressed at low level on healthy neurons (Beck et al., 2002) and astrocytes (Beck et 
al., 2002; Choi et al., 2007) and which is elevated on ischemic endothelial cells (Beck 
et al., 2002), neurons (Zhang et al., 2001; Beck et al., 2002; Hou et al., 2008) and 
astrocytes (Zhang et al., 2001; Beck et al., 2002) over as long as 30 days post-stroke 
(Table 1); and for angiopoietin receptors Tie-1 and Tie-2, which are hardly found in 
the healthy brain (Lin et al., 2001), but more robustly expressed on ischemic cerebral 
vessels (Lin et al., 2000; Lin et al., 2001; Croll and Wiegand, 2001; Zhang et al., 
2002) over 28 days post-stroke (Table 1).  
 
VEGF is not the only growth factor that together with its receptors is regulated 
upon ischemia in the brain parenchyma. De novo expression on neurons and 
astrocytes has previously been shown also for bFGF and its receptor (Liu et al., 
2006), G-CSF and its receptor (Schneider et al., 2005) and Epo receptor (Li et al., 
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2007). As such, parenchymal expression appears to be a more general feature of 
growth factors involved in neurovascular remodeling. 
 
1.3.5 Functionality of VEGF receptors in hypoxic-ischemic brain 
 
That VEGF and its receptors are upregulated upon stroke should alter the 
responsiveness of the brain tissue. This might explain why VEGF acts not only as 
angiogenic but also as neuroprotective and plasticity-promoting growth factor. To 
exert their function and initiate cytosolic signal responses, several requirements have 
to be fulfilled, which relate to (i) the phosphorylation of the receptors, (ii) the 
interaction of VEGF receptors, namely of RTK with non-RTK, and (iii) the interaction 
of VEGF receptors with integrins.  
 
Autophosphorylation of VEGF receptors. Activation of the RTK takes place 
upon VEGF binding via autophosphorylation (Roskoski, 2008). Two forms of 
autophosphorylation exist, i.e., cis-autophosphorylation, which implies that a RTK 
monomer catalyzes its own phosphorylation, and trans-autophosphorylation, in which 
two RTK monomers forming a homodimer mutually phosphorylate each other when 
exposed to VEGF (see Figure 2; Roskoski, 2008). Previous studies have shown that 
the RTK VEGFR-2 is indeed phosphorylated in the presence of VEGF after stroke 
and that VEGFR-2 phosphorylation goes along with downstream signal responses 
mediating neuronal survival and blood-brain barrier permeability (Kilic et al., 2006a). 
 
Besides forming homodimers, RTK are probably able to form heterodimers 
that similar to homodimers are thought to transactivate each other by reciprocal 
phosphorylation. Evidence for heterodimeric RTK transphosphorylation has 
previously been shown in pharmacological and immunoprecipitation studies for 
VEGFR-1 and VEGFR-2 (Autiero et al., 2003), as well as for VEGFR-2 and VEGFR-3 
(Dixelius et al., 2003). Whether transphosphorylation is relevant for VEGF receptor 
signaling in the brain remains unclear. 
 
VEGF receptor crosstalk. Tyrosine kinase activity is influenced by the 
crosstalk of RTK with non-RTK coreceptors, namely with NRP-1, as previously 
shown for VEGFR-2 (Fig. 3). When interacting with VEGFR-2, NRP-1 increases 
VEGFR-2’s binding affinity to VEGF165 (Fig. 3; Soker et al., 1996, 1998). As a result, 
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a ternary receptor complex is formed (RTK/ NRP-1/ VEGF) that exhibits enhanced 
signal transduction properties (Kawamura et al., 2008). That RTK and NRP-1 are co-
expressed upon ischemia argues in favour of a joint function of the two receptor 
subtypes. Observations that NRP-1 indeed promotes the activation of VEGFR-2 
upon VEGF165 treatment were recently made in vitro using porcine aortic endothelial 
cells (Kawamura et al., 2008). Evidence that this mechanism is also relevant in vivo 
after brain ischemia is still lacking. 
 
Interactions of VEGF receptors and integrins. Integrins are receptors for cell 
matrix molecules, such as collagen, laminin, fibronectin and vitronectin, which control 
the arrangement of vascular cells and the formation of the BBB (del Zoppo and 
Mabuchi, 2003). Integrins exhibit rapid expression changes following stroke. As such, 
the collagen receptor α1β1 strongly decreases within 2 hours after middle cerebral 
artery (MCA) occlusion in areas developing neuronal injury (Tagaya et al., 2001), 
whereas the vitronectin receptor αvβ3, which mediates endothelial and smooth 
muscle cell migration (Leavesley et al., 1993), was found to increase on non-capillary 
(>7.5 µm) microvessels (Okada et al., 1996; Abumiya et al., 1999). 
 
Observations that αvβ3 and VEGF were co-localized after ischemia (Abumiya 
et al., 1999) led to protein interaction studies showing that VEGFR-2 and β3 integrin 
are capable of mutually phosphorylating each other (Fig. 2; Mahabeleshwar et al., 
2007). The phosphorylation of β3 integrin was shown to be mediated by the tyrosine 
kinase c-Src (Mahabeleshwar et al., 2007), whereas VEGFR-2 phosphorylation was 
facilitated by αvβ3’s ligand, the matrix-bound sixth immunoglobin-like domain of the 
cell adhesion molecule L1 (Fig. 3; Hall and Hubbell, 2004). Deactivation of αvβ3 by a 
pharmacological inhibitor reduced VEGFR-2 phosphorylation after MCA occlusion, 
pointing towards the notion that αvβ3/ VEGFR-2 interaction is relevant in vivo 
(Shimamura et al., 2006).  
 
Due to their regionally select expression that differs between capillary and 
non-capillary microvessels (Abumiya et al., 1999), integrins may adjust vascular 
migration to environmental tissue needs (del Zoppo and Mabuchi, 2003). As such, 
the upregulation of αvβ3 on non-capillary, but not capillary microvessels may provide 
an explanation for why precapillary arterioles are so important for vascular sprouting. 
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Figure 3 (for legend see page 22) 
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Figure 3. Mechanisms of VEGF receptor activation. Three major mechanisms 
have been identified on how RTK activation occurs. A. When bound to VEGF, RTK 
dimerize and subsequently get activated by autophosphorylation. 
Autophosphorylation may take place in a way that each RTK catalyzes its own 
phosphorylation (cis-autophosphorylation) or that RTK mutually phosphorylate each 
other (trans-autophosphorylation). B. The non-RTK VEGF receptor NRP-1 is capable 
of presenting VEGF to RTK, thereby strengthening the VEGF-RTK interaction and 
facilitating cell signaling. C. Besides binding to non-RTK VEGF receptors, RTK are 
capable of interacting with integrins, namely αvβ3 integrin. Upon substrate binding, 
αvβ3 promotes RTK phosporylation. Phosporylated RTK in turn induces the 
phosporylation of β3 integrin, thus generating a positive feedback loop. The latter 
step is mediated by tyrosine kinase c-Src (from Hermann and Zechariah, 2009). 
 
 
1.3.6 Effect of other growth factors on VEGF and VEGF receptors 
 
 
Besides VEGF, several other growth factors also enhance the formation of new 
vessels. Some of them, such as angiopoietin-1 and Epo, themselves mobilize 
endothelial precursor cells or recruit hematopoietic precursor cells from the blood 
(Losordo and Dimmeler, 2004). This process of vasculogenesis, i.e., the formation of 
new vessels from immature cells, has long been considered to be a feature of 
embryonic tissues, but is meanwhile accepted to take place also in the adult brain in 
parallel to angiogenesis, i.e., the growth of new vessels out of existing ones (Asahara 
and Kawamoto, 2004).  
 
Not all growth factors, however, directly promote new vessel growth. In fact, 
some factors, including bFGF and Epo, have been suggested to exert their 
angiogenic function by stimulating the expression of VEGF and VEGF receptors on 
endothelial cells (Pepper and Mandriota, 1998; Wang et al., 2004). In case of bFGF 
and Epo, pharmacological inhibition of VEGFR-2 abolished the effects of the growth 
factors on capillary tube formation and new vessel growth (Seghezzi et al., 1998; 
Tille et al., 2001; Wang et al., 2004), indicating that VEGF indeed mediates their 
angiogenic effects. In case of Epo, de novo expression and secretion of VEGF on 
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neural progenitor cells is regulated via activation of PI3K/ Akt and ERK-1/2 pathways 
(Wang et al., 2008). Besides VEGF, Epo was shown to elevate bFGF, angiopoietin-2 
and Tie-1 levels in the ischemic brain (Keogh et al., 2007). 
 
 
VEGF-mediated vasculogenesis has previously also been shown for G-CSF, 
which promotes the recruitment of VEGFR-1+, VEGF-positive neutrophils as well as 
of circulating VEGFR-2+ endothelial progenitor cells in the blood (Ohki et al., 2005). 
Blockade of VEGFR-1 and to lesser extent VEGFR-2 abrogated the effect of G-CSF 
on new vessel growth, indicating that myelomonocytic cells play a role in the 
modelling of the vessels (Ohki et al., 2005). Not only growth factors but also statins 
increase VEGF, VEGFR-2 and brain derived neurotrophic factor (BDNF) levels in the 
brain, putatively by increasing subventricular zone precursor cell migration (Chen et 
al., 2005). Hence, VEGF appears to reflect a downstream signal in neurovascular 
remodelling that acts as common target of various angiogenic molecules. The 
combined evidence of various growth factor studies suggests that angiogenesis and 
vasculogenesis are closely linked in the adult ischemic brain and that VEGF plays a 
crucial role in both processes.  
 
 
1.4 Therapeutic potential of VEGF 
 
The effects of therapeutic VEGF delivery in the ischemic brain were analyzed in 
a total of thirty-four animal studies to date, which investigated actions of this growth 
factor on ischemic injury, blood-brain barrier disturbances, CBF and neurological 
recovery (summarized in Tables 2 and 3). Twenty-three of these studies were 
performed in rats, ten in mice and one in gerbils. Twenty-seven studies used 
reversible proximal (i.e., intraluminal) middle cerebral artery (MCA) occlusions. Five 
studies examined transcortical MCA occlusions (three permanent, two reversible), 
one study cerebral thromboembolism and one venous thrombosis.  
 
Recombinant VEGF, mostly of human origin, was delivered in sixteen studies. 
VEGF-secreting cells were administered in three studies (neural precursor/ stem 
cells [NPC] in one, bone marrow-derived stem cells [BMSC] in one, baby hamster 
kidney [BHK] cells in one study). Adeno-associated virus (AAV) vectors were used in 
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four studies, plasmids containing VEGF cDNA in two studies, transgenic mouse 
models expressing human VEGF under a neuronal promoter in three studies and one 
study used transferrin coupled liposomes. Five studies evaluated VEGF antagonists.  
  
In twenty-two studies, VEGF or VEGF antagonist was locally applied either by 
intracerebroventricular (ICV) or local brain delivery, or was induced by brain-specific 
expression. Twelve studies used systemic delivery strategies (intravenous [IV] in 
four, intraarterial [IA] in two, intraperitoneal [IP] in four studies and intranasal [IN] in 
two studies) for VEGF/ VEGF antagonist. Seventeen studies focussed on the acute 
injury phase, whereas sixteen studies involved post-acute assessments of functional 
neurological recovery up to twelve weeks post-stroke.  
 
 
1.4.1 Effect on neuronal survival and blood-brain barrier integrity 
 
 
Studies with therapeutic VEGF application revealed quite different effects 
depending on the route of growth factor delivery. As such, all twenty-one studies 
examining the effects of local (i.e., ICV or brain) application of VEGF, VEGF-
secreting cells or vectors on structural histological injury consistently revealed a 
reduction of ischemic brain damage that was evaluated by infarct volumetry in twelve 
and analysis of disseminated neuronal injury in nine studies (see Table 2). All 
thirteen studies examining the impact of VEGF on functional neurological recovery 
exhibited sensorimotor, coordination and cognitive improvements that persisted over 
as long as twelve weeks post-stroke (Table 2). Along with the reduction in ischemic 
injury, brain edema was reduced in three studies (Zhao et al 2010., Hayashi et al., 
1998; Bellomo et al., 2003) and remained unchanged in four studies (Harrigan et al., 
2003; Wang et al., 2005; Kilic et al., 2006a; Miki et al., 2007), whereas a single study 
using encapsulated VEGF-secreting cells reported an exacerbation of edema around 
the grafting site (Yano et al., 2005). The extravasation of serum proteins was 
reduced in two studies (Kaya et al., 2005; Herz et al., 2012) and increased in two 
studies (Wang et al., 2005; Kilic et al., 2006a). VEGF antagonization by neutralizing 
antibodies reduced edema formation in another study (Chi et al., 2007).  
 
 
                                          VEGF-induced angiogenesis in focal cerebral ischemia/ 25 
 A completely different picture resulted from the seven studies using systemic, 
i.e., IA, IV, IP, IN application strategies. As such, four out of six studies with systemic 
(IA, IV) VEGF delivery exhibited detrimental effects (Zhang et al., 2000; Abumiya et 
al., 2005; Kaya et al., 2005; Manoonkitiwongsa et al., 2004, 2006), reflected by an 
increase of brain injury in two studies, increased hemorrhagic transformation in two 
studies and increased microvascular injury and inflammation in one study (Table 3). 
One of these studies showed an increased permeability of the blood-brain barrier to 
gadolinium, Evans blue and fluorescein isothiocyanate (FITC) dextran (Zhang et al., 
2000), one study an increase in albumin extravasation (Kaya et al., 2005) and one 
study no changes in immunoglobulin G (IgG) extravasation (Table 3). Two studies 
utilized intranasal delivery strategy during the post acute stage, resulting in reduction 
of infarct volume and enhanced neurological recovery (Yang et al., 2009, 2010). Four 
studies using VEGF antagonists revealed a reduction of infarct volume (van Bruggen 
et al., 1999; Kimura et al., 2005; Chiba et al., 2008; Koyama et al., 2010) and three of 
them showed a reduction in brain edema (van Bruggen et al., 1999; Kimura et al., 
2005; Koyama et al., 2010), furthermore demonstrating that VEGF plays a 
detrimental role when systemically (in this case IP) applied (Table 3).  
 
The only study exhibiting an unequivocally beneficial effect of VEGF after 
systemic (IA) administration used a post-acute delivery strategy, in which the growth 
factor was applied together with stem cells starting two days after stroke (Chu et al., 
2005). This suggests that the time-point in addition to route of delivery might play a 
role in the actions of VEGF in the ischemic brain. Notably, all studies exhibiting 
unfavourable effects of VEGF used acute application strategies, in which the growth 
factor were delivered the day before, immediately after or one hour after the stroke 
(Table 3). 
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e 
o
f d
el
iv
er
y 
A
n
gi
o
ge
n
es
is 
Br
ai
n
 
in
jur
y 
 
Ed
em
a/
 
bl
o
o
d 
br
ai
n
 
ba
rr
ier
 
pe
rm
ea
bi
lit
y 
Ef
fe
ct
 
o
n
 
bl
o
o
d 
flo
w
 
 
N
eu
ro
lo
gi
ca
l e
ff
ec
t 
M
ec
ha
n
ism
s 
o
f a
ct
io
n
 
H
er
z 
et
 
al
.
 
(20
12
) 
C5
7B
L6
 
m
o
u
se
 
30
 
m
in
 
M
CA
 
o
cc
lu
si
o
n
/ 3
-
52
 
da
ys
 
re
pe
rfu
sio
n
 
rh
V
EG
F 1
65
 
(0.
02
 

g/
da
y) 
 
Lo
ca
l I
C
V
 
St
ar
tin
g 
3 
da
ys
 
af
te
r 
M
CA
 
o
cc
lu
si
o
n
 
N
o
t i
n
v
es
tig
at
ed
 
R
ed
u
ce
d 
se
co
n
da
ry
 
n
eu
ro
n
al
 
de
ge
n
er
at
io
n
 
an
d 
br
ai
n
 
at
ro
ph
y 
N
o
 
ch
an
ge
s 
in
 
Ig
G
 
ex
tr
av
as
at
io
n
 
an
d 
IC
A
M
-
1+
 
v
es
se
ls 
N
o
 
ch
an
ge
s 
in
 
LD
F 
du
rin
g 
isc
he
m
ia
 
an
d 
af
te
r 
re
pe
rfu
sio
n
 
Im
pr
o
v
ed
 
gr
ip
 
st
re
n
gt
h 
an
d 
co
o
rd
in
at
io
n
 
sk
ill
s,
 
as
so
ci
at
ed
 
w
ith
 
en
ha
n
ce
d 
ax
o
n
al
 
sp
ro
u
tin
g 
in
 
co
n
tr
al
es
io
n
al
 
co
rt
ic
o
ru
br
al
 
tr
ac
t 
V
EG
F 
in
du
ce
s 
im
m
u
n
o
su
pp
re
ss
io
n
 
in
 
bo
th
 
he
m
isp
he
re
s 
by
 
do
w
n
re
gu
la
tio
n
 
o
f 
br
o
ad
 
se
ts
 
o
f c
yt
o
ki
n
es
 
an
d 
ch
em
o
ki
n
es
 
re
qu
ire
d 
fo
r 
th
e 
re
cr
u
itm
en
t a
n
d 
ac
tiv
at
io
n
 
o
f i
m
m
u
n
e 
ce
lls
 
R
ei
tm
ei
r 
et
 
al
 
(20
12
) 
 
C5
7B
L6
 
m
o
u
se
 
30
 
m
in
 
M
CA
 
o
cc
lu
si
o
n
 
/ 3
-
52
 
da
ys
 
re
pe
rfu
sio
n
 
rh
V
EG
F 1
65
 
(0.
00
4 

g/
da
y 
an
d 
0.
02
 

g/
da
y) 
Lo
ca
l I
C
V
 
St
ar
tin
g 
3 
da
ys
 
af
te
r 
M
CA
 
o
cc
lu
si
o
n
 
In
cr
ea
se
d 
de
n
sit
y 
o
f 
CD
31
+
 
ca
pi
lla
rie
s 
bo
th
 
in
 
ip
sil
es
io
n
al
 
an
d 
co
n
tr
al
es
io
n
al
 
st
ria
tu
m
 
R
ed
u
ce
d 
sh
rin
ka
ge
 
o
f 
isc
he
m
ic
 
st
ria
tu
m
,
 
52
 
da
ys
 
po
st
 
isc
he
m
ia
 
 
N
o
t i
n
v
es
tig
at
ed
 
 
N
o
 
LD
F 
ch
an
ge
s 
du
rin
g 
isc
he
m
ia
 
an
d 
af
te
r 
re
pe
rfu
sio
n
 
Pr
o
gr
es
si
v
e 
im
pr
o
v
em
en
ts
 
in
 
gr
ip
 
st
re
n
gt
h 
an
d 
co
o
rd
in
at
io
n
 
sk
ill
s,
 
as
so
ci
at
ed
 
w
ith
 
en
ha
n
ce
d 
ax
o
n
al
 
sp
ro
u
tin
g 
in
 
co
n
tr
al
es
io
n
al
 
co
rt
ic
o
bu
lb
ar
 
tra
ct
 
V
EG
F 
in
hi
bi
ts
 
ca
sp
as
e-
3 
de
pe
n
da
n
t 
ap
o
pt
o
tic
 
in
jur
y,
 
po
st
 
ac
u
te
 
tis
su
e 
sh
rin
ka
ge
 
an
d 
en
ha
n
ce
s 
an
gi
o
ge
n
es
is.
 
M
M
P9
 
de
ac
tiv
at
io
n
 
by
 
V
EG
F 
re
su
lti
n
g 
in
 
la
ck
 
o
f a
x
o
n
al
 
sp
ro
u
tin
g 
in
 
le
si
o
n
ed
 
he
m
isp
he
re
.
 
Tr
an
sie
n
t d
o
w
n
re
gu
la
tio
n
 
o
f e
ph
rin
 
B1
,
ep
hr
in
 
B2
,
 
N
G
2 
an
d 
br
ev
ic
an
 
in
 
co
n
tr
al
es
io
n
a
l h
em
isp
he
re
 
en
ab
lin
g 
ax
o
n
a
l g
ro
w
th
 
Zh
ao
 
et
 
al
.
 
(20
10
) 
W
ist
ar
 
ra
t 
2 
hr
s 
M
CA
o
cc
lu
sio
n
 
/2
4 
hr
s 
-
7 
da
ys
 
re
pe
rfu
sio
n
 
rh
V
EG
F/
 
A
n
g1
 
o
r 
rh
V
EG
F 
tr
an
sf
ec
te
d 
ad
en
o
-
as
so
ci
at
ed
 
v
iru
s 
(V
EG
F 
n
o
t 
qu
an
tif
ie
d) 
 
Lo
ca
l I
C
V
 
8 
w
ee
ks
 
be
fo
re
 
M
CA
 
o
cc
lu
si
o
n
 
M
o
re
 
st
ro
n
gl
y 
in
cr
ea
se
d 
m
ic
ro
v
es
se
l 
pr
o
lif
er
at
io
n
 
af
te
r 
V
EG
F/
 
A
n
g1
 
th
an
 
V
EG
F 
de
liv
er
y 
45
%
 
re
du
ct
io
n
 
o
f i
n
fa
rc
t 
v
o
lu
m
e 
af
te
r 
V
EG
F/
 
A
n
g1
 
co
m
pa
re
d 
w
ith
 
V
EG
F 
de
liv
er
y 
al
o
n
e 
D
ec
re
as
ed
 
BB
B 
pe
rm
ea
bi
lit
y 
fo
llo
w
in
g 
V
EG
F/
 
A
n
g1
 
co
m
pa
re
d 
w
ith
 
V
EG
F 
de
liv
er
y 
al
o
n
e 
N
o
t i
n
v
es
tig
at
ed
 
M
ar
ke
d 
re
du
ct
io
n
 
in
 
n
eu
ro
lo
gi
ca
l s
ev
er
ity
 
sc
o
re
 
fo
llo
w
in
g 
V
EG
F/
 
A
n
g1
 
co
m
pa
re
d 
w
ith
 
V
EG
F 
de
liv
er
y 
al
o
n
e 
N
o
t i
n
v
es
tig
at
ed
 
W
an
g 
et
 
al
.
 
(20
09
) 
  
Sp
ra
gu
e–
D
aw
le
y 
ra
t  
 
30
 
m
in
 
M
CA
 
o
cc
lu
si
o
n
 
/ 8
 
w
ee
ks
 
re
pe
rfu
sio
n
 
rh
V
EG
F 1
65
 
ex
pr
es
sin
g 
pl
as
m
id
s  
Lo
ca
l I
C
V
 
15
 
m
in
s 
af
te
r 
M
CA
 
o
cc
lu
si
o
n
 
In
cr
ea
se
d 
n
u
m
be
r 
o
f 
Br
dU
+
 
an
d 
v
o
n
 
W
ill
eb
ra
n
d 
fa
ct
o
r+
 
v
es
se
ls 
R
ed
u
ct
io
n
 
o
f i
n
fa
rc
t v
o
lu
m
e 
In
cr
ea
se
d 
n
u
m
be
r 
o
f 
im
m
at
u
re
 
an
d 
m
at
u
re
 
(al
so
 
G
A
B
A
er
gi
c) 
n
eu
ro
n
s 
in
 
th
e 
co
rt
ex
 
N
o
t i
n
v
es
tig
at
ed
 
N
o
t i
n
v
es
tig
at
ed
 
N
o
t i
n
v
es
tig
at
ed
 
V
EG
F 
in
cr
ea
se
s 
n
eu
rit
e 
le
n
gt
h 
an
d 
en
ha
n
ce
s 
m
at
u
ra
tio
n
 
o
f s
tr
o
ke
-
in
du
ce
d 
co
rt
ic
al
 
n
eu
ro
ge
n
es
is 
an
d 
de
n
dr
ite
 
fo
rm
at
io
n
 
o
f n
ew
bo
rn
 
n
eu
ro
n
s 
 
Li
 
et
 
al
.
 
(20
09
) 
Sp
ra
gu
e–
D
aw
le
y 
ra
t 
2 
hr
s 
M
CA
 
o
cc
lu
si
o
n
/ 
21
 
da
ys
 
re
pe
rfu
sio
n
 
 
rh
V
EG
F 1
65
 
tr
an
sf
ec
te
d 
ad
en
o
-
as
so
ci
at
ed
 
v
iru
s 
(32
4.
5 
±
 
86
.
5 
pg
/m
l)  
Lo
ca
l I
C
V
 
21
 
da
ys
 
be
fo
re
 
M
CA
 
o
cc
lu
si
o
n
 
N
o
t i
n
v
es
tig
at
ed
 
 
R
ed
u
ct
io
n
 
o
f i
n
fa
rc
t v
o
lu
m
e 
N
o
t i
n
v
es
tig
at
ed
 
N
o
t i
n
v
es
tig
at
ed
 
Im
pr
o
v
ed
 
n
eu
ro
lo
gi
ca
l 
fu
n
ct
io
n
 
V
EG
F 
in
cr
ea
se
s 
th
e 
n
u
m
be
r 
o
f B
rd
U
+
 
an
d 
D
CX
+
 
ce
lls
 
in
 
th
e 
su
bv
en
tr
ic
u
la
r 
zo
n
e 
W
an
g 
et
 
al
.
 
(20
07
c) 
 
Sp
ra
gu
e-
D
aw
le
y 
ra
t 
30
 
m
in
 
M
CA
 
o
cc
lu
si
o
n
/ 1
 
hr
 
-
 
14
 
da
ys
 
re
pe
rfu
sio
n
 
rh
V
EG
F 1
65
 
cD
N
A
 
co
n
ta
in
in
g 
pl
as
m
id
s 
(10
 
µg
,
 
V
EG
F 
its
el
f n
o
t 
qu
an
tif
ie
d) 
Lo
ca
l I
C
V
 
 
15
,
 
12
0 
o
r 
36
0 
m
in
s 
af
te
r 
M
CA
 
o
cc
lu
si
o
n
 
In
cr
ea
se
d 
en
do
th
el
ia
l 
pr
o
lif
er
at
io
n
 
in
di
ca
tiv
e 
o
f 
an
gi
o
ge
n
es
is 
R
ed
u
ct
io
n
 
o
f i
n
fa
rc
t v
o
lu
m
e 
in
 
an
im
a
ls 
tr
ea
te
d 
at
 
15
 
m
in
 
o
r 
12
0 
m
in
,
 
bu
t n
o
t 3
60
 
m
in
 
af
te
r 
M
CA
 
o
cc
lu
sio
n
.
 
St
im
u
la
tio
n
 
o
f n
eu
ro
ge
n
es
is 
in
 
su
bv
en
tr
ic
u
la
r 
zo
n
e 
an
d 
st
ria
tu
m
 
N
o
t I
n
v
es
tig
at
ed
 
N
o
t I
n
v
es
tig
at
ed
 
N
o
t I
n
v
es
tig
at
ed
 
V
EG
F 
pr
o
m
o
te
s 
n
eu
ro
lo
gi
ca
l r
ec
o
v
er
y 
by
 
st
im
u
la
tin
g 
an
gi
o
ge
n
es
is?
 
Sh
en
 
et
 
al
.
 
(20
06
) 
CD
1 
m
o
u
se
 
45
 
m
in
 
M
CA
 
o
cc
lu
si
o
n
/ 1
-
14
 
da
ys
 
re
pe
rfu
sio
n
 
rh
V
EG
F 1
65
 
tr
an
sf
ec
te
d 
ad
en
o
-
as
so
ci
at
ed
 
v
iru
s 
(V
EG
F 
n
o
t 
qu
an
tif
ie
d) 
Lo
ca
l I
C
V
 
 
5 
da
ys
 
be
fo
re
 
M
CA
 
o
cc
lu
si
o
n
 
N
o
t i
n
v
es
tig
at
ed
 
55
%
 
re
du
ct
io
n
 
o
f i
n
fa
rc
t 
v
o
lu
m
e,
 
de
cr
ea
se
 
o
f D
N
A
 
fra
gm
en
te
d 
ce
lls
 
N
o
t i
n
v
es
tig
at
ed
 
N
o
t i
n
v
es
tig
at
ed
 
N
o
t i
n
v
es
tig
at
ed
 
V
EG
F 
re
du
ce
s 
ca
sp
as
e-
3 
ac
tiv
ity
 
W
an
g 
et
 
al
.
 
(20
06
c) 
Sp
ra
gu
e-
D
aw
le
y 
ra
t 
90
 
m
in
 
M
CA
 
o
cc
lu
si
o
n
/ 8
 
w
ks
 
re
pe
rfu
sio
n
 
 
V
EG
F 1
65
 
(0.
24
 
µg
/d
ay
) 
Lo
ca
l I
C
V
 
24
 
ho
u
rs
 
af
te
r 
M
CA
 
o
cc
lu
si
o
n
 
 
N
o
t i
n
v
es
tig
at
ed
 
N
o
t i
n
v
es
tig
at
ed
 
N
o
t i
n
v
es
tig
at
ed
 
N
o
t i
n
v
es
tig
at
ed
 
Pe
rs
ist
en
tly
 
im
pr
o
v
ed
 
co
gn
iti
v
e 
an
d 
se
n
so
rim
o
to
r 
de
fic
its
,
 
en
ha
n
ce
d 
le
ar
n
in
g 
an
d 
m
em
o
ry
 
N
o
t i
n
v
es
tig
at
ed
 
 
K
ay
a 
et
 
al
.
 
(20
05
) 
 
Sw
iss
 
al
bi
n
o
 
m
o
u
se
 
 
90
 
m
in
 
M
CA
 
o
cc
lu
si
o
n
/ 2
4 
hr
s 
re
pe
rfu
sio
n
 
V
EG
F 1
65
 
(15
µg
/k
g) 
  
Lo
ca
l I
C
V
 
1 
hr
 
o
r 
3 
hr
s 
af
te
r 
re
pe
rfu
sio
n
 
N
o
t i
n
v
es
tig
at
ed
 
35
%
 
an
d 
46
%
 
re
du
ct
io
n
 
o
f 
in
fa
rc
t v
o
lu
m
e,
 
re
du
ce
d 
n
u
m
be
r 
o
f T
U
N
EL
 
po
sit
iv
e 
ce
lls
 
D
ec
re
as
ed
 
al
bu
m
in
 
ex
tr
av
as
at
io
n
 
N
o
 
LD
F 
ch
an
ge
s 
du
rin
g 
isc
he
m
ia
 
an
d 
af
te
r 
re
pe
rfu
sio
n
 
D
ec
re
as
ed
 
m
o
to
r 
de
fic
its
 
V
EG
F 
ac
tiv
at
es
 
PI
3K
/A
kt
 
pa
th
w
ay
 
 
B
el
lo
m
o
 
et
 
al
.
 
(20
03
) 
M
o
n
go
lia
n
 
ge
rb
il 
3-
4 
m
in
 
bi
la
te
ra
l 
CC
A
 
o
cc
lu
sio
n
/ 
2-
12
 
da
ys
 
re
pe
rfu
sio
n
 
V
EG
F 
tr
an
sf
ec
te
d 
ad
en
o
-
as
so
ci
at
ed
 
v
iru
s 
(V
EG
F 
n
o
t 
qu
an
tif
ie
d) 
Lo
ca
l I
C
V
 
6 
o
r 
12
 
da
ys
 
be
fo
re
 
isc
he
m
ia
 
N
o
t i
n
v
es
tig
at
ed
 
D
ec
re
as
ed
 
n
eu
ro
n
al
 
in
jur
y 
in
 
CA
1 
re
gi
o
n
 
D
ec
re
as
ed
 
br
ai
n
 
ed
em
a 
 
N
o
t i
n
v
es
tig
at
ed
 
Im
pr
o
v
em
en
t i
n
 
pa
ss
iv
e 
av
o
id
an
ce
 
te
st
 
N
o
t i
n
v
es
tig
at
ed
 
H
ar
rig
an
 
et
 
al
.
 
(20
03
) 
Sp
ra
gu
e-
D
aw
le
y 
ra
t 
2 
hr
s 
M
CA
 
o
cc
lu
si
o
n
/ 2
4 
hr
s 
re
pe
rfu
sio
n
 
rh
V
EG
F 1
65
 
(0.
12
 
µg
/d
ay
) 
Lo
ca
l I
C
V
 
1 
w
ee
k 
be
fo
re
 
M
CA
 
o
cc
lu
si
o
n
 
N
o
t i
n
v
es
tig
at
ed
 
R
ed
u
ct
io
n
 
o
f c
o
rt
ic
al
 
in
fa
rc
t 
v
o
lu
m
e,
 
n
o
 
ch
an
ge
 
in
 
su
bc
o
rt
ic
al
 
in
fa
rc
t v
o
lu
m
e 
N
o
 
ch
an
ge
s 
in
 
br
ai
n
 
ed
em
a 
N
o
 
ch
an
ge
s 
in
 
CB
F 
(14
C-
iso
pr
o
py
l-
io
do
a
m
ph
et
a
m
in
e 
au
to
ra
di
o
gr
ap
hy
) 
N
o
t i
n
v
es
tig
at
ed
 
R
ed
u
ct
io
n
 
in
 
in
fa
rc
t d
u
e 
to
 
n
eu
ro
pr
o
te
ct
iv
e 
ra
th
er
 
th
an
 
an
gi
o
ge
n
ic
 
ef
fe
ct
s 
Su
n
 
et
 
al
.
 
(20
03
) 
Sp
ra
gu
e-
D
aw
le
y 
ra
t 
 
90
 
m
in
 
M
CA
 
o
cc
lu
si
o
n
/ 3
-
28
 
da
ys
 
re
pe
rfu
sio
n
 
V
EG
F 1
65
 
(0.
24
 
µg
/d
ay
) 
  
Lo
ca
l I
C
V
 
24
 
hr
s 
to
 
3 
da
ys
 
af
te
r 
M
CA
 
o
cc
lu
si
o
n
 
Tw
o
 
fo
ld
 
in
cr
ea
se
 
in
 
n
ew
ly
 
fo
rm
ed
 
v
W
F+
 
bl
o
o
d 
v
es
se
ls 
in
 
de
n
ta
te
 
gy
ru
s 
an
d 
pe
n
u
m
br
a 
35
%
 
re
du
ct
io
n
 
o
f i
n
fa
rc
t 
v
o
lu
m
e 
th
at
 
pe
rs
ist
ed
 
fo
r 
4 
w
ee
ks
.
 
R
ed
u
ct
io
n
 
o
f c
el
l 
in
jur
y,
 
ce
ll 
sh
rin
ka
ge
 
an
d 
D
N
A
 
cl
ea
v
a
ge
 
N
o
t i
n
v
es
tig
at
ed
 
N
o
t i
n
v
es
tig
at
ed
 
Pe
rs
ist
en
t d
ec
re
as
e 
in
 
n
eu
ro
lo
gi
ca
l s
ev
er
ity
 
sc
o
re
 
V
EG
F 
st
im
u
la
te
s 
an
gi
o
ge
n
es
is,
 
pr
o
m
o
te
s 
n
eu
ro
ge
n
es
is 
an
d 
re
du
ce
s 
ca
sp
as
e-
3-
de
pe
n
de
n
t n
eu
ro
n
al
 
de
at
h 
VEGF-induced angiogenesis in focal cerebral ischemia/ 26
     Ta
bl
e
 
2.
 
An
im
a
l s
tu
di
es
 
w
ith
 
lo
ca
l V
EG
F 
de
liv
e
ry
 
st
ra
te
gi
e
s 
(co
n
tin
u
e
d) 
   Li
 
et
 
al
.
 
(20
08
) 
C5
7B
L6
 
an
d 
V
EG
F-
B 
de
fic
ie
n
t 
m
o
u
se
 
 
Tr
an
sc
o
rt
ic
al
 
M
CA
 
o
cc
lu
si
o
n
/(n
o
 
re
pe
rfu
sio
n
)/ 
24
hr
s 
su
rv
iv
al
 
V
EG
F-
B 
 
(2.
2 

g/

l)  
Lo
ca
l b
ra
in
 
(co
rt
ic
al
) 
Im
m
ed
ia
te
ly
 
be
fo
re
 
M
CA
 
o
cc
lu
si
o
n
 
N
o
 
ef
fe
ct
 
o
n
 
n
o
rm
al
 
o
r 
pa
th
o
lo
gi
ca
l 
an
gi
o
ge
n
es
is 
in
 
th
e 
ey
e 
50
%
 
in
cr
ea
se
 
o
f b
ra
in
 
da
m
ag
e 
in
 
V
EG
F-
B 
de
fic
ie
n
t m
ic
e 
an
d 
32
%
 
re
du
ct
io
n
 
in
 
in
fa
rc
t v
o
lu
m
e 
in
 
C5
7B
L6
 
m
ic
e 
N
o
t i
n
v
es
tig
at
ed
 
N
o
t i
n
v
es
tig
at
ed
 
N
o
t i
n
v
es
tig
at
ed
 
A
n
ti-
ap
o
pt
o
tic
 
ac
tiv
ity
 
o
f V
EG
F-
B 
is 
m
ed
ia
te
d 
by
 
do
w
n
re
gu
la
tio
n
 
o
f B
H
3-
o
n
ly
 
pr
o
te
in
 
an
d 
o
th
er
 
ce
ll 
de
at
h 
re
la
te
d 
pr
o
te
in
s 
v
ia
 
V
EG
FR
-
1 
Ch
i e
t a
l. 
(20
07
) 
   
W
ist
ar
 
ra
t 
Tr
an
sc
o
rt
ic
al
 
M
CA
 
o
cc
lu
si
o
n
 
(no
 
re
pe
rfu
sio
n
)/ 
1 
hr
 
su
rv
iv
al
 
 
A
n
ti-
rh
V
EG
F 1
65
 
an
tib
o
dy
 
(25
 

g 
an
d 
75

g/
 
an
im
a
l) 
Lo
ca
l b
ra
in
 
(co
rt
ic
al
) 
1 
hr
 
be
fo
re
 
an
d 
im
m
ed
ia
te
ly
 
af
te
r 
M
CA
 
o
cc
lu
si
o
n
 
N
o
t i
n
v
es
tig
at
ed
 
N
o
t i
n
v
es
tig
at
ed
 
Tr
an
sf
er
 
co
ef
fic
ie
n
t (
K
i) o
f 
14
C-

-
a
m
in
o
iso
bu
ty
ric
 
ac
id
 
re
du
ce
d,
 
in
di
ca
tin
g 
de
cr
ea
se
d 
ed
em
a 
N
o
t i
n
v
es
tig
at
ed
 
N
o
t i
n
v
es
tig
at
ed
 
Bl
o
o
d 
br
ai
n
 
ba
rr
ier
 
di
sr
u
pt
io
n
 
du
rin
g 
isc
he
m
ia
 
is 
at
 
lea
st
 
in
 
pa
rt
 
du
e 
to
 
en
do
ge
n
o
u
s 
V
EG
F 
al
re
ad
y 
pr
es
en
t o
r 
pr
o
du
ce
d 
im
m
ed
ia
te
ly
 
af
te
r 
M
CA
 
o
cc
lu
si
o
n
 
 
H
ay
as
hi
 
et
 
al
.
 
(19
98
) 
W
ist
ar
 
ra
t 
 
90
 
m
in
 
M
CA
 
o
cc
lu
si
o
n
/ 2
4-
48
 
hr
s 
re
pe
rfu
sio
n
 
G
el
-
fo
a
m
 
so
ak
ed
 
rh
V
EG
F 1
65
 
 
(9 
n
g/
an
im
a
l) 
Lo
ca
l b
ra
in
 
(co
rt
ic
al
) 
Im
m
ed
ia
te
ly
 
af
te
r 
re
pe
rfu
sio
n
 
N
o
t i
n
v
es
tig
at
ed
 
R
ed
u
ct
io
n
 
o
f i
n
fa
rc
t v
o
lu
m
e 
an
d 
D
N
A
 
fra
gm
en
te
d 
ce
lls
 
D
ec
re
as
ed
 
br
ai
n
 
ed
em
a 
in
 
V
EG
F 
tr
ea
te
d 
an
im
a
ls 
N
o
t i
n
v
es
tig
at
ed
 
N
o
t I
n
v
es
tig
at
ed
 
R
ed
u
ct
io
n
 
in
 
H
sp
72
 
im
m
u
n
o
re
ac
tiv
ity
 
 
in
di
ca
tin
g 
re
du
ct
io
n
 
o
f i
sc
he
m
ic
 
st
re
ss
 
Em
er
ic
h 
et
 
al
.
 
(20
10
) 
Sp
ra
gu
e–
D
aw
le
y 
ra
t 
60
 
m
in
 
M
CA
 
 
o
cc
lu
si
o
n
/ 1
 
hr
 
–
 
21
 
da
ys
 
re
pe
rfu
sio
n
 
V
EG
F 1
65
 
(1µ
g/
an
im
a
l) 
Lo
ca
l b
ra
in
 
(st
ria
ta
l)  
15
 
m
in
 
be
fo
re
 
M
CA
 
o
cc
lu
si
o
n
 
N
o
t i
n
v
es
tig
at
ed
 
 
>
80
%
 
re
du
ct
io
n
 
o
f 
 
le
sio
n
 
v
o
lu
m
e 
 
N
o
t i
n
v
es
tig
at
ed
 
 
N
o
 
ch
an
ge
s 
in
 
LD
F 
du
rin
g 
isc
he
m
ia
 
an
d 
af
te
r 
re
pe
rfu
sio
n
 
 
D
ec
re
as
ed
 
m
o
to
r 
as
ym
m
et
rie
s 
an
d 
im
pr
o
v
ed
 
n
eu
ro
lo
gi
ca
l 
fu
n
ct
io
n
 
 
N
o
t i
n
v
es
tig
at
ed
 
 
M
ik
i e
t a
l. 
(20
07
) 
W
ist
ar
 
ra
t 
2 
hr
s 
M
CA
 
o
cc
lu
si
o
n
/ 2
-
28
 
da
ys
 
re
pe
rfu
sio
n
 
rh
V
EG
F 1
65
-
tr
an
sf
ec
te
d 
bo
n
e 
m
ar
ro
w
 
st
em
 
ce
lls
 
(B
M
SC
s) 
(34
 
pg
 
V
EG
F/
g 
pr
o
te
in
) 
Lo
ca
l b
ra
in
 
(st
ria
ta
l) 
24
 
ho
u
rs
 
af
te
r 
M
CA
 
o
cc
lu
si
o
n
 
N
o
t i
n
v
es
tig
at
ed
 
R
ed
u
ct
io
n
 
o
f i
n
fa
rc
t v
o
lu
m
e 
N
o
 
ch
an
ge
s 
in
 
br
ai
n
 
w
at
er
 
co
n
te
n
t 
N
o
t i
n
v
es
tig
at
ed
 
D
ec
re
as
ed
 
m
o
to
r 
de
fic
its
 
in
 
BM
SC
 
an
d 
BM
SC
+
V
EG
F 
tr
ea
te
d 
an
im
a
ls,
 
ef
fe
ct
 
m
o
st
 
pr
o
n
o
u
n
ce
d 
in
 
V
EG
F+
BM
SC
 
gr
o
u
p 
N
o
t i
n
v
es
tig
at
ed
 
 
Y
an
o
 
et
 
al
.
 
(20
05
) 
 
W
ist
ar
 
ra
t 
90
 
m
in
 
M
CA
 
o
cc
lu
si
o
n
/ 1
-
14
 
da
ys
 
re
pe
rfu
sio
n
 
En
ca
ps
u
la
te
d 
V
EG
F 1
65
 
se
cr
et
in
g 
ba
by
 
ha
m
st
er
 
ki
dn
ey
 
(B
H
K
) c
el
ls 
(11
.
2 
n
g 
V
EG
F/
da
y) 
Lo
ca
l b
ra
in
 
(st
ria
ta
l) 
  
6 
da
ys
 
be
fo
re
 
M
CA
 
o
cc
lu
si
o
n
 
In
cr
ea
se
d 
de
n
sit
y 
o
f 
n
ew
ly
 
fo
rm
ed
 
la
m
in
in
+
 
v
es
se
ls,
 
n
o
 
ch
a
n
ge
 
in
 
v
es
se
l 
di
a
m
et
er
 
48
%
 
re
du
ct
io
n
 
o
f i
n
fa
rc
t 
siz
e,
 
re
du
ct
io
n
 
in
 
D
N
A
 
fra
gm
en
te
d 
ce
lls
 
Ex
ac
er
ba
te
d 
ed
em
a 
ar
o
u
n
d 
BH
K
 
gr
af
t 6
 
da
ys
 
af
te
r 
ca
ps
u
le 
pl
ac
em
en
t i
n
 
an
im
a
ls 
re
ce
iv
in
g 
V
EG
F 
tr
an
sf
ec
te
d 
ce
lls
 
N
o
 
LD
F 
ch
an
ge
s 
du
rin
g 
isc
he
m
ia
 
an
d 
af
te
r 
re
pe
rfu
sio
n
 
En
ha
n
ce
d 
pe
rf
o
rm
an
ce
 
o
n
 
ac
ce
le
ra
tin
g 
ro
ta
ro
d 
at
 
lea
st
 
u
n
til
 
14
 
da
ys
 
af
te
r 
M
CA
 
o
cc
lu
sio
n
 
V
EG
F 
ac
tiv
at
es
 
PI
3K
/A
kt
 
pa
th
w
ay
 
Zh
u
 
et
 
al
.
 
(20
05
a) 
Sp
ra
gu
e-
D
aw
le
y 
ra
t 
2 
hr
s 
M
CA
 
o
cc
lu
si
o
n
/ 2
-
12
 
w
ee
ks
 
re
pe
rfu
sio
n
 
V
EG
F 1
21
-
tr
an
sf
ec
te
d 
n
eu
ra
l s
te
m
 
ce
lls
 
(V
EG
F 
n
o
t 
qu
an
tif
ie
d) 
Lo
ca
l b
ra
in
 
(st
ria
ta
l) 
  
3 
da
ys
 
af
te
r 
M
CA
 
o
cc
lu
si
o
n
 
 
  
N
o
t i
n
v
es
tig
at
ed
 
N
o
t i
n
v
es
tig
at
ed
 
N
o
t i
n
v
es
tig
at
ed
 
N
o
t i
n
v
es
tig
at
ed
 
D
ec
re
as
ed
 
m
o
to
r 
de
fic
its
 
fro
m
 
2 
to
 
12
 
w
ee
ks
 
in
 
V
EG
F-
tr
an
sf
ec
te
d 
st
em
 
ce
ll 
gr
o
u
p,
 
n
o
n
-
tr
an
sf
ec
te
d 
st
em
 
ce
lls
 
w
ith
o
u
t e
ffe
ct
 
N
o
t i
n
v
es
tig
at
ed
 
W
an
g 
et
 
al
.
 
(20
07
a) 
C5
7B
L6
 
m
o
u
se
 
Tr
an
sc
o
rt
ic
al
 
 
M
CA
 
o
cc
lu
si
o
n
 
(no
 
re
pe
rfu
sio
n
)/ 
7-
28
 
da
ys
 
su
rv
iv
al
 
rh
V
EG
F 1
65
 
 
u
n
de
r 
N
SE
 
pr
o
m
o
te
r 
 
(21
.
74
 
n
g/
g 
pr
o
te
in
)  
Tr
an
sg
en
ic
 
br
ai
n
 
ex
pr
es
sio
n
 
Co
n
st
itu
tiv
e 
rh
V
EG
F 
o
v
er
ex
pr
es
si
o
n
 
N
o
t i
n
v
es
tig
at
ed
 
R
ed
u
ct
io
n
 
o
f i
n
fa
rc
t 
v
o
lu
m
e,
 
st
im
u
la
tio
n
 
o
f 
n
eu
ro
ge
n
es
is 
in
 
su
bv
en
tr
ic
u
la
r 
zo
n
e 
N
o
t i
n
v
es
tig
at
ed
 
N
o
t i
n
v
es
tig
at
ed
 
D
ec
re
as
ed
 
m
o
to
r 
de
fic
its
 
V
EG
F 
pr
o
m
o
te
s 
n
eu
ro
lo
gi
ca
l r
ec
o
v
er
y 
by
 
st
im
u
la
tin
g 
an
gi
o
ge
n
es
is?
 
 
K
ili
c 
et
 
al
.
 
(20
06
a) 
C5
7B
L6
 
m
o
u
se
 
90
 
m
in
 
M
CA
 
o
cc
lu
si
o
n
/ 2
4 
hr
s 
re
pe
rfu
sio
n
 
rh
V
EG
F 1
65
 
 
u
n
de
r 
N
SE
 
pr
o
m
o
te
r 
(21
.
74
 
n
g/
g 
pr
o
te
in
)  
 
Tr
an
sg
en
ic
 
br
ai
n
 
ex
pr
es
sio
n
 
Co
n
st
itu
tiv
e 
rh
V
EG
F 
o
v
er
ex
pr
es
si
o
n
 
N
o
t i
n
v
es
tig
at
ed
 
R
ed
u
ct
io
n
 
o
f i
n
fa
rc
t v
o
lu
m
e 
th
at
 
w
as
 
ab
o
lis
he
d 
af
te
r 
de
liv
er
y 
o
f P
I3
K
/ A
kt
 
in
hi
bi
to
r 
W
o
rt
m
an
n
in
 
In
cr
ea
se
 
o
f I
gG
 
ex
tr
av
as
at
io
n
 
by
 
V
EG
F 
is 
co
m
pl
et
el
y 
ab
o
lis
he
d 
by
 
W
o
rt
m
an
n
in
 
N
o
t i
n
v
es
tig
at
ed
 
D
ec
re
as
ed
 
m
o
to
r 
de
fic
its
 
re
v
er
se
d 
to
 
th
e 
le
v
el
s 
o
f w
ild
 
ty
pe
 
an
im
a
ls 
af
te
r 
W
o
rt
m
an
n
in
 
tr
ea
tm
en
t 
V
EG
F 
ac
tiv
at
es
 
PI
3K
/A
kt
 
an
d 
ER
K
1/
2 
an
d 
de
ac
tiv
at
es
 
p3
8 
an
d 
JN
K
1/
2 
pa
th
w
ay
s.
 
PI
3K
/A
kt
 
in
hi
bi
tio
n
 
re
v
er
se
s 
n
eu
ro
pr
o
te
ct
io
n
 
an
d 
bl
o
o
d 
br
ai
n
 
ba
rr
ier
 
le
ak
a
ge
.
 
N
eu
ro
pr
o
te
ct
iv
e 
ef
fe
ct
 
m
ed
ia
te
d 
by
 
V
EG
FR
-
2 
th
at
 
is 
de
 
n
o
vo
 
ex
pr
es
se
d 
o
n
 
isc
he
m
ic
 
n
eu
ro
n
s 
an
d 
ac
tiv
at
ed
 
by
 
V
EG
F?
 
W
an
g 
et
 
al
.
 
(20
05
) 
C5
7B
L6
 
m
o
u
se
 
90
 
o
r 
30
 
m
in
 
M
CA
 
o
cc
lu
si
o
n
/ 
24
 
an
d 
72
 
hr
s 
re
pe
rfu
sio
n
 
rh
V
EG
F 1
65
 
 
u
n
de
r 
N
SE
 
pr
o
m
o
te
r 
(21
.
74
 
n
g/
g 
pr
o
te
in
)  
 
Tr
an
sg
en
ic
 
br
ai
n
 
ex
pr
es
sio
n
 
Co
n
st
itu
tiv
e 
rh
V
EG
F 
o
v
er
ex
pr
es
si
o
n
 
In
cr
ea
se
d 
de
n
sit
y 
o
f 
n
ew
ly
 
fo
rm
ed
 
V
EG
FR
2+
 
v
es
se
ls 
in
 
ce
re
br
al
 
co
rt
ex
 
an
d 
st
ria
tu
m
 
 
R
ed
u
ct
io
n
 
o
f i
n
fa
rc
t v
o
lu
m
e 
an
d 
D
N
A
-
fra
gm
en
te
d 
ce
lls
 
 
In
cr
ea
se
 
o
f s
o
di
u
m
 
flu
o
re
sc
ei
n
 
ex
tr
av
as
at
io
n
,
 
n
o
 
ch
an
ge
 
in
 
br
ai
n
 
ed
em
a 
 
58
 
%
 
CB
F 
de
cr
ea
se
 
in
 
isc
he
m
ic
,
 
59
%
 
in
cr
ea
se
 
in
 
n
o
n
-
isc
he
m
ic
 
co
rt
ex
 
 
(14
C-
io
do
an
tip
yr
in
e 
au
to
ra
di
o
gr
ap
hy
) 
D
ec
re
as
ed
 
m
o
to
r 
de
fic
its
 
 
R
ed
u
ct
io
n
 
o
f i
n
jur
y 
n
o
t d
u
e 
to
 
he
m
o
dy
n
a
m
ic
 
im
pr
o
v
em
en
t, 
bu
t r
at
he
r 
du
e 
to
 
n
eu
ro
pr
o
te
ct
iv
e 
ef
fe
ct
 
th
at
 
in
v
o
lv
es
 
ca
sp
as
e-
3 
in
hi
bi
tio
n
 
VEGF-induced angiogenesis in focal cerebral ischemia/ 27
    Ta
bl
e
 
3.
 
An
im
a
l s
tu
di
es
 
w
ith
 
sy
st
e
m
ic
 
VE
G
F 
de
liv
e
ry
 
st
ra
te
gi
e
s 
  
A
u
th
o
rs
 
A
n
im
a
l 
sp
ec
ie
s 
St
ro
ke
 
m
o
de
l 
D
o
se
 
R
o
u
te
 
o
f 
de
liv
er
y 
Ti
m
e 
o
f d
el
iv
er
y 
A
n
gi
o
ge
n
es
is 
Br
ai
n
 
in
jur
y 
 
Ed
em
a/
 
bl
o
o
d 
br
ai
n
 
ba
rr
ier
 
pe
rm
ea
bi
lit
y 
Ef
fe
ct
 
o
n
 
bl
o
o
d 
flo
w
 
N
eu
ro
lo
gi
ca
l e
ff
ec
t 
M
ec
ha
n
ism
s 
o
f a
ct
io
n
 
M
an
o
o
n
ki
tiw
o
n
gs
a 
 
et
 
al
.
 
(20
04
, 
20
06
) 
 
Sp
ra
gu
e-
D
aw
le
y 
ra
t 
4 
hr
s 
M
CA
 
o
cc
lu
si
o
n
/ 7
 
da
ys
 
re
pe
rfu
sio
n
 
rh
V
EG
F 1
65
 
(2,
 
8 
o
r 
60
 
µg
) 
Sy
st
em
ic
 
IA
 
Im
m
ed
ia
te
ly
 
af
te
r 
re
pe
rfu
sio
n
 
fo
r 
7 
da
ys
 
H
ig
h 
V
EG
F 
do
se
 
in
du
ci
n
g 
n
ew
 
v
es
se
l 
fo
rm
at
io
n
,
 
lo
w
 
an
d 
in
te
rm
ed
ia
te
 
do
se
s 
w
ith
o
u
t e
ffe
ct
 
H
ig
h 
V
EG
F 
do
se
 
n
o
t 
in
flu
en
ci
n
g 
n
eu
ro
n
al
 
su
rv
iv
al
,
 
lo
w
 
an
d 
in
te
rm
ed
ia
te
 
do
se
s 
w
ith
 
n
eu
ro
pr
o
te
ct
iv
e 
ef
fe
ct
 
 
H
ig
h 
V
EG
F 
do
se
 
in
du
ci
n
g 
m
ic
ro
v
as
cu
la
r 
in
jur
y,
 
lo
w
 
an
d 
in
te
rm
ed
ia
te
 
do
se
s 
 
w
ith
o
u
t e
ffe
ct
 
N
o
t i
n
v
es
tig
at
ed
 
N
o
t i
n
v
es
tig
at
ed
 
A
n
gi
o
ge
n
ic
 
V
EG
F 
do
se
s,
 
in
cr
ea
sin
g 
m
ac
ro
ph
a
ge
 
ac
cu
m
u
la
tio
n
.
 
In
fla
m
m
at
o
ry
 
ch
an
ge
s 
co
n
tr
ib
u
tin
g 
to
 
in
jur
y 
fo
llo
w
in
g 
sy
st
em
ic
 
V
EG
F 
de
liv
er
y 
A
bu
m
iy
a 
et
 
al
.
 
(20
05
) 
 
Sp
ra
gu
e-
D
aw
le
y 
ra
t 
2 
hr
s 
M
CA
 
o
cc
lu
si
o
n
/ 1
–
72
hr
s 
re
pe
rfu
sio
n
 
rh
V
EG
F 
(0.
3 
µg
/k
g) 
 
Sy
st
em
ic
 
IA
 
Im
m
ed
ia
te
ly
 
af
te
r 
re
pe
rfu
sio
n
 
N
o
 
ch
an
ge
s 
in
 
v
es
se
l 
n
u
m
be
r 
Ex
ac
er
ba
tio
n
 
o
f 
he
m
o
rr
ha
gi
c 
tr
an
sf
o
rm
at
io
n
.
 
N
o
 
ch
an
ge
 
in
 
isc
he
m
ic
 
ce
ll 
in
jur
y 
N
o
 
ch
an
ge
s 
in
 
se
ru
m
 
Ig
G
 
ex
tr
av
as
at
io
n
 
N
o
t i
n
v
es
tig
at
ed
 
N
o
 
ch
an
ge
s 
N
o
t i
n
v
es
tig
at
ed
 
Zh
ao
 
et
 
al
.
 
(20
11
) 
  
Sp
ra
gu
e–
D
aw
le
y 
ra
t 
Pe
rm
an
en
t M
CA
 
o
cc
lu
si
o
n
 
(no
 
re
pe
rfu
sio
n
)/ 
1-
21
 
da
ys
 
su
rv
iv
al
 
 
rh
V
EG
F 
de
liv
er
ed
 
v
ia
 
tr
an
sf
er
rin
-
co
u
pl
ed
 
lip
o
so
m
es
 
(T
f-V
EG
F-
PL
; 
80
 
µg
 
V
EG
F/
 
an
im
a
l);
 
co
n
tr
o
l 
an
im
a
ls 
re
ce
iv
in
g 
V
EG
F-
co
n
ta
in
in
g 
lip
o
so
m
es
 
n
o
t 
co
u
pl
ed
 
w
ith
 
tr
an
sf
er
rin
 
(V
EG
F-
PL
) o
r 
n
o
rm
al
 
sa
lin
e 
Sy
st
em
ic
 
IV
 
  
48
 
h 
af
te
r 
M
CA
 
o
cc
lu
si
o
n
 
 
In
cr
ea
se
d 
v
as
cu
la
r 
de
n
sit
y 
in
 
pe
n
u
m
br
a 
o
f T
f-V
EG
F-
PL
 
tr
ea
te
d 
m
ic
e 
co
m
pa
re
d 
w
ith
 
V
EG
F-
PL
 
an
d 
sa
lin
e 
tr
ea
te
d 
m
ic
e 
R
ed
u
ce
d 
in
fa
rc
t v
o
lu
m
e 
in
 
Tf
-
V
EG
F-
PL
 
tr
ea
te
d 
m
ic
e 
N
o
t i
n
v
es
tig
at
ed
 
 
LD
F 
in
cr
ea
se
d 
in
 
Tf
-
V
EG
F-
PL
 
tr
ea
te
d 
m
ic
e 
af
te
r 
21
 
da
ys
 
 
En
ha
n
ce
d 
n
eu
ro
lo
gi
ca
l 
re
co
v
er
y 
in
 
an
im
a
ls 
tr
ea
te
d 
w
ith
 
Tf
-
V
EG
F-
PL
 
 
N
o
t i
n
v
es
tig
at
ed
 
 
Ch
u
 
et
 
al
.
 
(20
05
) 
Sp
ra
gu
e-
D
aw
le
y 
ra
t 
90
 
m
in
 
M
CA
 
o
cc
lu
si
o
n
/ 3
5 
da
ys
 
re
pe
rfu
sio
n
 
rh
V
EG
F 1
65
 
(50
 
µg
/k
g) 
 
Sy
st
em
ic
 
IV
 
N
eu
ra
l s
te
m
 
ce
lls
 
(N
SC
s) 
in
jec
te
d 
24
 
hr
s,
 
V
EG
F 
48
 
hr
s 
af
te
r 
M
CA
 
o
cc
lu
si
o
n
 
In
cr
ea
se
d 
de
n
sit
y 
o
f 
en
do
th
el
ia
l b
ar
rie
r 
an
tig
en
 
(E
B
A
)+
 
 
v
es
se
ls 
in
 
V
EG
F,
 
N
SC
 
an
d 
N
SC
+
V
EG
F 
tr
ea
te
d 
an
im
a
ls 
(la
tte
r 
w
ith
 
st
ro
n
ge
st
 
in
cr
ea
se
) 
N
SC
+
V
EG
F 
tr
ea
te
d 
gr
o
u
ps
 
w
ith
 
le
ss
er
 
de
gr
ee
 
o
f b
ra
in
 
at
ro
ph
y 
co
m
pa
re
d 
to
 
o
th
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1.4.2 Effect on brain hemodynamics 
 
One study with systemic (i.e., intravenous) VEGF delivery reported that VEGF 
acutely influences cerebral hemodynamics after stroke (Zhang et al., 2000). In that 
study, the authors used a permanent focal brain ischemia model, i.e., cerebral 
thromboembolism in rats, in which an exacerbation of brain edema and histological 
injury were noted. By means of arterial spin-labeling techniques, the authors 
demonstrated a short-lasting increase of CBF that persisted over as long as three 
hours after VEGF delivery (Zhang et al., 2000). No CBF changes were seen in non-
ischemic animals. The authors concluded that the enhanced blood flow may be 
attributed to an enhanced vasorelaxation that was interpreted as response of the 
ischemic vasculature to this growth factor (Zhang et al., 2000). 
 
In order to analyze whether hemodynamic changes are involved in VEGF’s 
survival-promoting actions in paradigms going along with structural neuroprotection, 
Wang et al. (2005) studied VEGF’s effects on CBF by 14C-iodoantipyrine 
autoradiography in a model of constitutive CNS-specific VEGF overexpression. Using 
intraluminal MCA occlusions, the authors observed that VEGF increased regional 
CBF in areas outside the MCA territory, but reduced regional CBF in ischemic tissue 
(Wang et al., 2005). These data were interpreted as hemodynamic steal 
phenomenon, indicating that VEGF may redirect the blood from hemodynamically 
compromised to non-ischemic regions. In view of the observation that VEGF reduced 
infarct size in that stroke model and that neuroprotection went along in the reduction 
of caspase-3 levels in ischemic brain areas (Wang et al., 2005), the authors 
concluded that direct neuroprotective rather than hemodynamic effects are involved 
in the survival-promoting effects of VEGF.  
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1.4.3 Effect on brain plasticity and neurogenesis 
 
 
A number of studies suggest that VEGF induces neurite outgrowth in vitro and 
in vivo (Rosenstein et al., 2003; Pitzer et al., 2003). That VEGF promotes brain 
plasticity is supported by the role of VEGF’s receptor NRP-1 as receptor for axonal 
repulsion molecules belonging to the semaphorin family (He and Tessier-Lavigne., 
1997). In fact, VEGF and semaphorins (in particular collapsin-1/ semaphorin-3D) 
compete to similar sites of the extracellular domain of NRP-1 (Miao et al., 1999). 
Collapsin-1 bound to neuropilin was shown to reduce lamellipodia motility in one 
study, resulting in cytoskeleton collapse, whereas VEGF attenuated the collapsin-1-
induced lamellipodia repulsion (Miao et al., 1999). Semaphorin-3A, another repellent 
guidance cue, was found to induce apoptosis again through NRP-1 in another study, 
which was abolished by VEGF, resulting in survival, proliferation and migration of 
neural progenitor cells (Bagnard et al., 2001). Notably, the cellular actions of 
semaphorin-3A required RTK activity, semaphorin-3A’s effects being blocked after 
VEGFR-1 inhibition. The authors interpreted their findings as further proof of 
evidence that NRP-1 acts as co-receptor for VEGFR-1. 
 
 Only few studies analyzed VEGF’s effects on neuronal plasticity after stroke. 
By using ICV delivery of either recombinant VEGF or VEGF165-containing plasmids in 
rats, and using constitutively VEGF-overexpressing mice, Sun et al. (2003), (Wang et 
al., 2009) and (Wang et al. 2007a, 2007c) reported that VEGF increased 
neurogenesis in the subventricular zone and striatum, increased neurite length,  
enhanced maturation of stroke-induced cortical neurogenesis and dendrite formation 
of newborn neurons (Table 2). As neurogenesis was also accompanied by improved 
sensorimotor recovery even when VEGF delivery was initiated as late as 24 hours 
after stroke (Sun et al., 2003), the authors concluded that newly formed neurons 
might contribute to the functional improvements. Whether and how VEGF influences 
the plasticity of pre-existing neurons and the remodelling of white matter tract 
systems is still unknown. Using anterograde tract-tracers, neutralizing antibodies 
directed against the growth-repulsive Nogo-A protein (Wiessner et al., 2003) as well 
as bone marrow-derived stem cells (Liu et al., 2007) have recently been shown to 
promote corticospinal sprouting contralesional to a stroke under conditions going 
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along with successful neurological recovery. Epo, a factor which is known to induce 
VEGF production in the brain, has been shown to promote neuronal survival and 
angiogenesis and decrease reactive astrogliosis thereby promoting perilesional 
tissue remodelling (Reitmeir et al., 2011). Recent investigations have shown the 
progressive improvements in neurological recovery and coordination skills in mice 
after chronic VEGF treatment, owing to the transient downregulation of ephrin b1, 
ephrin b2, NG2 and brevican (Reitmeir et al., 2012) and by inducing 
immunosuppression (Herz et al., 2012).  
 
 
1.5 Angiogenesis, hyperlipidemia and stroke: Open questions 
 
 
From studies in peripheral artery occlusive disease and coronary artery 
disease, great enthusiasm had emerged already more a decade ago (Isner et al., 
1996; Hendel et al., 2000) that by therapeutic angiogenesis it might become possible 
to promote neurological recovery also after stroke. In coronary artery disease, 
experimental studies rapidly led to clinical trials, in which gene therapy approaches 
using intramyocardial or intracoronary delivery of VEGF cDNA plasmids or adenoviral 
VEGF vectors were tested. In these studies, VEGF delivery led to improvements of 
functionally relevant readouts, e.g., coronary vascularization or electrocardiography 
(ECG) abnormalities in some (Mäkinen et al., 2002; Hedman et al., 2003; Stewart et 
al., 2006), but not other (Rajagopalan et al., 2003; Kastrup et al., 2005) studies. In 
ischemic stroke, VEGF-induced permeability has precluded clinical studies in stroke 
until now. The question arises, whether there are applications that might nonetheless 
be considered for VEGF in the stroke brain. In order to answer this question, a 
number of open issues still have to be addressed. 
 
Among previous studies analyzing VEGF’s effects in the stroke brain, 
particularly few studies assessed clinically relevant stroke models, which might 
translate to conditions in elderly patients in which cerebral hemodynamics is 
compromised. Only one study assessed VEGF’s effects in a clinically relevant 
thromboembolism model (Table 3). All studies used young animals with otherwise 
intact vasculature. Most importantly, no studies tested experimental conditions, in 
which CBF was compromised already prior to the stroke event and no studies tested 
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atherosclerotic or aged animals. Studies in animals with hemodynamic disturbances 
could mimic the clinical situation of the chronically hypoperfused brain, which is not 
rarely a problem in clinical neurology. Importantly, only two studies analyzed 
hemodynamic consequences of VEGF treatment until now (Zhang et al., 2000; Wang 
et al., 2005). To date, there is still no convincing evidence that therapeutic 
angiogenesis indeed improves blood flow. Studies in elderly animals may be of 
interest, since HIF-1α expression and binding activity and VEGF expression are age-
dependently suppressed in smooth muscle cells, both under physiologic conditions 
and during hypoxia (Rivard et al., 2000). 
 
Most studies in the past used acute treatment paradigms, delivering VEGF 
immediately or up to seven days following stroke (Tables 2, 3). Only four studies 
evaluated prophylactic treatments beginning two weeks or less prior to the stroke 
(Tables 2, 3). No study has so far assessed, which receptor mediates the angiogenic 
and neuroprotective effects of VEGF after stroke. Post-acute treatments are highly 
relevant with respect to future clinical developments, as based on the permeability 
changes it may be expected that the risk of brain edema and hemorrhagic 
transformation does not play a similar role in the post-acute stroke phase. Such 
studies should contribute additional insights into the effects of VEGF on brain 
plasticity processes and how VEGF promotes motor and non-motor neurological 
recovery. Prophylactic studies might contribute insights into the question as whether 
VEGF may be useful in stroke prevention, e.g., under conditions of severe 
intracranial stenosis. 
 
Based on the existing literature and in view of the above-described open 
questions, future studies should clarify the questions, (a) whether an increased 
vessel density translates to improvements of CBF in the hemodynamically 
compromised brain, (b) how hemodynamic improvement contribute to motor and 
non-motor recovery, (c) which are the actions of VEGF not only in animals with 
preserved vasculature, where previous studies were performed, but also in hitherto 
animals with pre-existing atherosclerosis.  
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2 AIM OF THE STUDY 
 
Major efforts have been made in human patients with atherosclerosis to 
stimulate angiogenesis by the delivery of vascular endothelial growth factor (VEGF) 
or of viral vectors or plasmids containing the VEGF transgene (Simons and Ware, 
2003; Hermann and Chopp, 2012; Hermann and Zechariah, 2009; Potente et al., 
2011). Functionally relevant improvements were noticed only in some (Mäkinen et 
al., 2002; Henry et al., 2003; Hedman et al., 2003; Stewart et al., 2006; Ruel et al., 
2008; Kukula et al., 2011) but not other (Rajagopalan et al., 2003; Kastrup et al., 
2005; Ripa et al., 2006) clinical studies, in which VEGF was delivered for the 
prevention of coronary heart or peripheral occlusive artery disease. Thus, the 
translation of therapeutic angiogenesis from bench to bedside still hampers.  
 
 
2.1 Part I: Effect of therapeutic angiogenesis on cerebral hemodynamics, 
brain metabolism and recovery 
 
 
In animal models of ischemic stroke, VEGF-induced angiogenesis has 
previously been shown to result in structural neuroprotection and functional 
neurological recovery (Zhang et al., 2000; Wang et al., 2005). Whether the 
preservation of ischemic tissue was a consequence of enhanced CBF or of the 
neuroprotective effects of VEGF was unclear (Hermann and Zechariah, 2009). VEGF 
promotes neuronal survival both directly via VEGF's receptor VEGFR2 (Kilic et al., 
2006a) and indirectly by release of BDNF (Chen et al., 2005). 
 
Although several studies have examined VEGF-induced angiogenesis in 
models of focal and global cerebral ischemia (Hermann and Zechariah, 2009), only 
two have evaluated the extent to which VEGF influences regional CBF in the 
ischemic brain. In a magnetic resonance imaging study, acute VEGF infusion was 
shown to induce a transient CBF increase in ischemic brain tissue lasting over 3 
hours (Zhang et al., 2000), which was interpreted as vasorelaxation induced by this 
growth factor. In mice expressing human VEGF chronically under a neuron-specific 
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NSE promoter, increased CBF was observed in non-ischemic brain areas alongside 
a reduction in CBF in ischemic brain areas (Wang et al.,2005), suggesting that the 
enhanced angiogenesis had induced a hemodynamic steal flow. The mice examined 
expressed human VEGF throughout the brain, resulting in globally increased vessel 
densities (Wang et al.,2005). CBF was scarcely altered in this mouse line under 
physiological conditions (Vogel et al., 2004). 
 
Raising further questions whether newly formed blood vessels are functional, 
loss of pericyte coverage of endothelial cells has previously been noticed in Matrigel 
assays following VEGF treatment in a model of platelet-derived growth factor 
(PDGF)-BB-induced angiogenesis (Greenberg et al., 2008). Immunoprecipitation 
studies revealed a hitherto unknown VEGF-induced deactivation of PDGF-BB's 
receptor PDGFRβ that is expressed on pericytes, which was mediated by the 
interaction of PDGFRβ with VEGF's receptor VEGFR2 (Greenberg et al., 2008). 
Inhibition of VEGFR2 prevented the formation of this receptor complex and restored 
pericyte coverage, thus stabilizing the newly formed blood vessels (Greenberg et al., 
2008). Whether interactions between VEGFR2 and PDGFRβ take place in vivo in the 
brain and whether they are relevant for ischemic stroke was unknown. 
 
In order to evaluate the concept of VEGF-induced therapeutic angiogenesis, 
we exposed mice that had been treated with VEGF, injected into the cerebral 
ventricles over a period of up to 21 days, to focal cerebral ischemia. In a 
multiparametric imaging strategy, combining CBF and cerebral protein synthesis 
(CPS) autoradiography, regional adenosine-5'-triphosphate (ATP) bioluminescence 
imaging and histochemical techniques, we then assessed the effects of VEGF-
induced angiogenesis on regional CBF, brain metabolism and neurovascular 
integrity. 
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2.2 Part II: Effect of hyperlipidemia on VEGF-induced angiogenesis and 
associated benefits. 
 
 
 Reflecting the deposition of lipids into vessel walls either due to dietary habits 
or genetic predisposition, atherosclerosis is frequently accompanied by lipid 
abnormalities. In ischemic stroke, about half of all patients exhibit hyperlipidemia 
(Sacco et al., 2008; Hermann and Chopp, 2012), and hyperlipidemic subjects in turn 
have an elevated stroke mortality (Iso et al., 1989; Horenstein et al., 2002). 
Chronically increased cholesterol levels trigger a number of vascular events, such as 
oxidative stress, endothelial dysfunction, BBB disturbances and vascular 
inflammation (Duan et al., 2000; Matter et al., 2006; Osto et al., 2008; ElAli et al., 
2011b).  
 
 Although the consequences of elevated cholesterol levels for vascular integrity 
are well-established and spontaneous angiogenesis is compromised (Van Belle et 
al., 1997; Duan et al., 2000; Jang et al., 2000), it is still unknown how hyperlipidemia 
influences angiogenesis in response to VEGF treatment after ischemia. Due to 
severe hemodynamic abnormalities, patients with intracranial atherosclerosis, which 
is particularly strongly associated with dyslipidemia (Turan et al., 2010; Park et al., 
2011), might specifically be eligible for angiogenic therapies. Thus, the question how 
hyperlipidemic blood vessels respond to VEGF possesses high clinical relevancy.  
 
 To elucidate effects of hyperlipidemia on VEGF-induced angiogenesis, we 
herein treated normocholesterolemic or hypercholesterolemic C57BL6 wildtype and 
apolipoprotein-E (ApoE)-/- mice prophylactically with normal saline or VEGF for 21 
days and exposed these animals to focal cerebral ischemia. We subsequently 
analysed changes in brain capillary density, regional CBF, energy state, histological 
brain injury and pericyte coverage of brain vessels.  
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3 MATERIALS AND METHODS 
 
 
 3.1 Experimental animal groups 
 
All experiments were performed with government approval according to the 
National Institutes of Health guidelines for the care and use of laboratory animals. 
 
For part 1. In the first set, 38 adult male C57BL6/j mice (20–25 grams) were 
randomly assigned to 6 groups that were treated with vehicle (normal saline) or 
recombinant human VEGF165 (rhVEGF165) for a period of 3, 10 or 21 days (6-7 
animals/ group). The MCA was then occluded for 90 min, followed by 24 hours of 
reperfusion. These animals were used for histochemical analysis of angiogenesis, 
ischemic injury and for molecular biological studies.  
 
 A second set of 12 mice were assigned to two groups (6 animals each) and 
treated with vehicle or rhVEGF165 for 21 days. The MCA was then occluded for 90 
min, followed by 60 min of reperfusion. These animals were used for CBF and CPS 
double autoradiography and regional ATP bioluminescence imaging. 
 
For part 2. Male C57BL6/j mice and ApoE-/- mice were used that were fed with 
either regular or cholesterol-rich Western diet for six weeks starting at the age of 3 
weeks. We have previously analysed plasma cholesterol levels following this diet 
exposure, showing that plasma cholesterol levels were 56.6±17.4 mg/dl in wildtype 
animals kept on regular (i.e., normal) diet, 220.4±58.0 mg/dl in wildtype animals on 
Western diet, 470.9±276.9 mg/dl in ApoE-/- animals on normal diet and 1279.1±528.2 
mg/dl in ApoE-/- animals on Western diet in the end of the 6-week diet regime (ElAli et 
al., 2011b). 
 
 In a first set of studies, male wildtype mice and ApoE-/- mice that were fed with 
normal or Western diet were randomly assigned to eight groups receiving 
miniosmotic pump implantation into the left lateral ventricle at the age of six weeks 
(i.e., three weeks after the initiation of the dietary regimen), via which vehicle (0.9% 
NaCl) or rhVEGF165 (0.02 µg/day) were administered over 21 days. At the age of nine 
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weeks, when animals had a body weight of 20-25 g, animals were exposed to 90 
minutes middle cerebral artery (MCA) occlusion followed by 24 hours of reperfusion. 
These animals were used for histochemical analysis of angiogenesis, pericyte 
coverage, ischemic injury and molecular biological studies (n=6-7 animals/ group).  
 
A second set of C57BL6/j and ApoE-/- mice kept on normal or Western diet 
were assigned to four groups treated with vehicle or VEGF165 over 21 days in an 
identical way. At the age of nine weeks, animals were submitted to 90 minutes MCA 
occlusion followed by 60 minutes of reperfusion. These animals were used for CBF 
and CPS double autoradiography and for regional ATP bioluminescence imaging (6 
animals/ group). 
      
3.2 Delivery of recombinant human VEGF165 
 
           Cannulae linked to miniosmotic pumps (Alzet 2004, Palo Alto, CA, U.S.A.) 
were implanted during 1.5% isoflurane anaesthesia (30% O2, remainder N2O) into 
the left lateral ventricle (1 mm lateral to bregma/ 2.5 mm below brain surface), for 
administration of normal saline or recombinant human VEGF165 (Peprotech, 
Hamburg, Germany; 0.02 µg/day). After implantation wounds were carefully sutured, 
anaesthesia was discontinued and animals were returned to their cages. 
 
 3.3 Induction of focal cerebral ischemia 
 
           Focal cerebral ischemia was induced during 1.5% isoflurane anaesthesia 
(30% O2, remainder N2O) using an intraluminal technique. Briefly, a midline neck 
incision was made and the left common carotid artery (CCA) and external carotid 
artery (ECA) were isolated and ligated. A microvascular clip (Aesculap; Tuttlingen, 
Germany) was temporarily placed on the internal carotid artery (ICA) and a 200µm 
silicon-coated nylon monofilament (Doccol Corporation, USA) was directed through 
the ICA, (avoiding the pterygopalatine artery (PPA)) until the origin of MCA. The 
monofilament was left in place for 90 minutes and then withdrawn to initiate 
reperfusion. Rectal temperature was maintained between 36°C and 37°C using a 
feedback-controlled heating system throughout the surgical procedures. Laser 
Doppler flow (LDF) was measured during the experiments up to 30 minutes after 
reperfusion using a flexible fibreoptic probe attached to the skull overlying the core of 
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the MCA territory. In the first set of experiments, anaesthesia was discontinued after 
this procedure. Wounds were sutured and animals returned to their cages. After 24 
hours, animals were reanaesthetized, and sacrificed by transcardiac perfusion with 
20 ml heparinised normal saline solution followed by 20 ml of normal saline. In the 
second set of experiments, animals remained under anaesthesia for delivery of 
radioactive tracers. Brains were removed and cut on a cryostat into 20 µm thick 
coronal sections that were retrieved at the rostrocaudal level of the bregma, which 
represents the level of the midstriatum. In addition, tissue samples were collected 
from the ischemic and contralateral non-ischemic MCA territory (striatum and 
overlying parietal cortex) for Western blotting, G-ELISA experiments and proteases 
activity assays. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 4: Middle cerebral artery occlusion model for focal cerebral ischemia. 
Representative pictures showing the introduction of silicon coated monofilament 
through the ICA impeding cerebral blood flow to the MCA supplied regions in the 
brain.  
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3.4 Evaluation of brain capillary densities 
 
20 µm cryostat sections were prepared from brains of animals sacrificed 24 
hours after reperfusion. In sections obtained from the rostrocaudal level of the mid-
striatum, i.e., the site of maximum extension of the MCA territory, brain capillaries 
were evaluated by fluorescence immunohistochemistry using a rat anti-platelet and 
endothelial cell adhesion molecule-1 (PECAM-1; CD31) antibody (BD Biosciences, 
San Diego, CA, U.S.A.) (Kilic et al., 2006b). Stainings were evaluated by counting the 
number of positive vessel profiles intersecting the 10 horizontal and 10 vertical lines 
of a 500 µm x 500 µm grid in a fluorescent microscope (Olympus, BX41, Germany). 
A total of three regions of interest (ROI) in the parietal cortex and four in the lateral 
striatum were evaluated within the MCA territory both ipsilateral and contralateral to 
the stroke. Means were calculated for all ROI that were used for further analysis. 
 
 
 3.5 Analysis of infarct volume 
 
Cryostat sections 1 mm apart were stained with cresyl violet (Wang et al., 
2005). The border between infarcted and healthy tissue was outlined using image 
analysis software (Image J; National Institutes of Health) and the infarct volume was 
quantified by subtracting the area of intact tissue in the ischemic and contralateral 
non-ischemic hemisphere (Zechariah et al., 2010). 
 
 
3.6 Serum IgG extravasation studies 
 
Brain sections obtained from the mid-striatum were processed for serum IgG 
immunohistochemistry. 20 µm thick cryostat brain sections obtained from the 
midstriatum level were rinsed slightly for 5 min at room temperature in 0.1 M 
phosphate buffered saline (PBS), inorder to preserve endogenous intravascular IgG 
and was fixed with 4% paraformaldehyde / 0.1 M PBS (Kilic et al., 2006a) for 15 min 
at 4°C. Endogenous peroxidases were blocked by heating the brain sections with 
methanol/ 0.3% hydrogen peroxide (H2O2). Brain sections were then immersed in 0.1 
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M PBS containing 5% bovine serum albumin and normal goat serum (1:1000) and 
were incubated for 1h in biotinylated goat antimouse IgG (sc-2039; Santa Cruz 
Biotechnology, Nunningen, Switzerland) and stained with an avidin peroxidase kit 
(Vectastain Elite; Vector Labs., Burlingname, CA) and diaminobenzidine (DAB; 
Sigma, Deisenhofen, Germany). Brain sections were then immersed in alcohol bath 
and xylene, coverslipped and were used for analysis. Stained sections were scanned 
and converted into gray values. Sections were densitometrically analyzed by 
evaluating a sample of 1 x 1 mm in the core of the MCA territory (striatum and 
overlying cortex), from which background staining in the contralateral MCA territory 
was subtracted (Zechariah et al., 2010). A total of two sections were evaluated for 
each animal, of which mean values were calculated.              
 
 
3.7 Gelatin zymography for matrix metalloproteinase (MMP)-9 
 
Brain samples obtained from the ischemic and contralateral non-ischemic 
MCA territory were homogenized, lysated, supplemented with 5% protease inhibitor 
cocktail, and sonicated. Protein concentrations were determined using the Bradford 
assay. MMP-9 (gelatinase-B) activity was assessed by zymography as described 
(Zechariah et al., 2010). Briefly, 25 µg proteins were mixed with 5X non-reducing 
loading buffer for 15 min at room temperature and subjected to sodium 
dodecylsulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) using 9% 
acrylamide-bis gel containing 0.1% gelatin (Sigma). Gels were removed, washed and 
incubated for 1 hr at room temperature with slight shaking in modified enzymatic 
activation buffer (50 mM Tris-HCl, 6 mM CaCl2, 1.5 µM ZnCl2, pH 7.4) containing 
2.5% Triton X-100 to remove SDS and to restore gelatinase activity. Gels were then 
incubated for 24 hr at 37°C in modified enzymatic activation buffer. After 24 hrs gels 
were stained using Coomassie brilliant blue R-250 (Bio-Rad) and then were 
immersed in destaining solution (40% methanol, 10% acetic acid, 50% water) and 
2% acetic acid. Protein extracts of all animals belonging to the same group were 
pooled for zymography. A total of four different gelatin gels were prepared for all 
experimental conditions. These gels were dried, digitized and densitometrically 
analyzed. 
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3.8 Microvessel isolation and protein extraction 
 
Relative abundance of some proteins is much higher in the brain 
microvessels, compared to whole brain lysates which makes it difficult to investigate 
the expression changes of these proteins in whole brain homogenates. In order to 
overcome this issue, we isolated brain microvessels using dextran separation 
technique which yielded 99% pure microvessels. 
 
Tissue samples from animals belonging to the same group were pooled and 
were homogenised in a glass homogenizer (Teflon®) using ice-cold microvessel 
isolation buffer (MIB; 15 mM HEPES, 147 mM NaCl, 4 mM KCl, 3 mM CaCl2 and 12 
mM MgCl2), supplemented with 5% protease inhibitor cocktail (P8340; Sigma, 
Deisenhofen, Germany) and 1% phosphatase inhibitor cocktail 2 (P5726; Sigma). 
The resulting homogenates were centrifuged at 3,200 rpm for 10 min at 4°C and the 
pellets were resuspended in 20% dextran (MW 64,000-76,000; D4751, Sigma) in 
MIB. These suspensions were centrifuged again at 6,500 rpm for 20 min at 4°C and 
the microvessel rich pellets were resuspended in MIB and filtered through two nylon 
filters of 100 µm and 30 µm mesh sizes (Millipore, Schwalbach, Germany). The 
quality of the isolated pellets was checked using the microscope and were stored at -
80°C until use. The isolated microvessels were homogenised and lysated in NP-40 
lysis buffer supplemented with 5% protease inhibitor cocktail and 1% phosphatase 
inhibitor cocktail, sonificated at 40% power and the protein concentrations were 
measured using Bradford assay kit with an iMark Microplate Reader (Bio-Rad, 
Hercules, Ca, USA) (ElAli and Hermann, 2011a). 
 
 
3.9 Western blot analysis 
 
Protein lysates were obtained from whole brain tissue and extracted crude 
microvessels using samples collected from the ischemic and contralateral non-
ischemic MCA territory (ElAli, and Hermann, 2011a). The lysates were pooled, 
resolved by SDS-PAGE and transferred into polyvinylidene fluoride (PVDF) 
membranes. Membranes were immersed in blocking solution and incubated 
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overnight with goat anti-intercellular adhesion molecule (ICAM)-1 (BAF 796; R&D 
Systems, Minneapolis, MN, U.S.A.) or rabbit anti-N-cadherin (4061; Millipore, 
Schwalbach, Germany) antibody, diluted 1:1000. Membranes were rinsed, incubated 
in secondary antibody and exposed to photoluminescence solution. Protein loading 
was controlled using a mouse anti-β-actin antibody (4967; Millipore). Blots were 
repeated at least three times to confirm reproducibility, corrected to β-actin and 
protein levels were analyzed densitometrically.  
 
3.10 Analysis of Rac1 Rho GTPase by G-LISATM  
 
Rac1 activity was analyzed by G-LISATM Rac activation assay (BK125; 
Cytoskeleton, Frankfurt, Germany) using protein lysates from cerebral microvessels, 
according to the manufacturer’s protocol and as described (ElAli, and Hermann, 
2011a). Absorbance was measured at 490 nm using the iMark microplate reader 
(Bio-Rad, Hercules, CA, U.S.A.). 
 
3.11 CBF and CPS double-autoradiography 
 
Fifteen minutes after reperfusion, 150 µCi L-[4, 5-3H] leucine (specific activity 
151 Ci/mmol; Amersham, Braunschweig, Germany) was administered 
intraperitoneally, followed by an intraperitoneal injection of 10 µCi 4-iodo-N-methyl-
[14C] antipyrine (Amersham) 43 minutes later. After a further two minutes, animals 
were instantly frozen in liquid nitrogen. Blood samples were obtained from the heart, 
in which the activity of 4-iodo-N-methyl-[14C] antipyrine was measured. Brains were 
removed and cut into 20 µm thick sections that were mounted on poly-l-lysine coated 
slides. These were exposed for 14 days, together with 14C and 3H standards on 14C-
Hyperfilm (Amersham) for CBF autoradiography. Brain slices were then incubated for 
24 h in 10% trichloroacetic acid to remove labeled free leucine and metabolites other 
than proteins, and subsequently re-exposed for the same duration to perform 3H 
autoradiography of 3H-labeled proteins using Hyperfilm 3H (Amersham) (Maeda et 
al., 2000; Hermann et al., 2001). Regional CBF was calculated as described 
previously (Wang et al., 2005; Maeda et al., 2000) by calibration with the 14C- and 3H-
standards, and radioactivity values measured in the blood. In the calibrated sections, 
regional CBF was determined in four ROI in the ischemic lateral striatum and three 
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ROI in the overlying parietal cortex (all inside MCA territory). For each animal, mean 
values were formed for all ROI.  
 
3.12 Regional ATP bioluminescence imaging 
 
For ATP measurement, frozen sections were freeze-dried and coated with a 
layer of frozen reaction mix containing the enzymes, coenzymes and cofactors 
necessary for evoking ATP-specific bioluminescence (Kogure and Alonso, 1978; 
Mies et al., 1991). The tissue/enzyme bilayer was thawed and light emissions were 
recorded using a CCD camera.  
 
 
3.13 Evaluation of metabolic penumbra 
 
The CPS-deficient and ATP-depleted area was determined on the CPS 
autoradiography and ATP bioluminescence images by outlining areas with preserved 
CPS and ATP in both hemispheres at the level of the mid-striatum. The metabolic 
penumbra was calculated from these results by subtracting the ATP preserved area 
from the CPS deficient area (Mies et al., 1991). 
 
 
3.14 Evaluation of pericyte coverage of brain capillaries 
 
Cryostat sections from the level of the mid-striatum were processed for double 
immunohistochemistry using rabbit anti-desmin (Abcam, Cambridge, UK) and rat 
anti-CD31 (BD Biosciences) (Greenberg et al., 2008; Helfrich et al., 2010). 
 
 To evaluate pericyte coverage of brain capillaries, the percentage of pericyte 
positive microvessels was counted in seven ROI’s (three in the parietal cortex and 
four in the lateral striatum) ipsilateral and contralateral to the stroke, out of which 
mean values were formed.  
 
To evaluate further, the volume changes in pericyte coverage, confocal 3D 
stacks were obtained using laser scanning microscope (LSM 510; Carl Zeiss 
MicroImaging, Jena, Germany) using 20 µm sections scanned at 2 µm intervals, 
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which were viewed using Zeiss LSM image browser and analyzed using ImageJ 
software. In these stacks, CD31+ capillaries and desmin+ pericytes were outlined, 
allowing for the evaluation of capillary and pericyte volumes, respectively, which were 
integrated for all levels, resulting in capillary and pericyte volumes, from which 
volume ratios were formed. 
 
 
3.15 Evaluation of pericytic injury and expression of VEGF receptors 
 
 
Cryostat sections from the level of the mid-striatum were processed for double 
immunohistochemistry using rabbit anti-desmin (Abcam, Cambridge, UK), rabbit anti-
cleaved caspase-3 (AB3623, Millipore), goat anti-VEGFR2 (AF644; R&D Systems) 
and rat anti-VEGFR1 (MAB471; R&D Systems) antibodies (Greenberg et al., 2008; 
Helfrich et al., 2010). To evaluate DNA fragmentation in pericytes, terminal 
transferase biotinylated-dUTP nick end-labeling (TUNEL) was performed using the 
fluorescein in situ cell death detection kit (11684795910; Roche, Basel, Switzerland), 
followed by immunohistochemistry for desmin. Brain sections doublestained for 
desmin, VEGR2, VEGFR1 and cleaved caspase-3 were used to evaluate the 
presence of VEGF receptors on pericytes and to test, if ischemic pericytes express 
activated caspase-3. In sections processed for TUNEL and desmin DNA 
fragmentation was evaluated. For the latter analyses, seven ROI were evaluated 
(three in the parietal cortex and four in the lateral striatum), with the investigator 
being blinded for experimental conditions at all stages of the data analysis.  
 
3.16 Statistics 
 
LDF recordings were evaluated by repeated measurement analysis of 
variance (ANOVA) with values determined at 15 min intervals during MCA occlusion 
and at 5 min intervals after reperfusion.  
 
For part 1. Capillary density, infarct volume, IgG extravasation, and all other 
histochemical studies comparing four or six groups were evaluated by two-way 
ANOVA, of which significant results are reported in the text. For those variables 
exhibiting significant differences, two-tailed t-tests were computed as post-hoc tests. 
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Changes in CBF, ATP depletion and the metabolic penumbra were analyzed by two-
tailed t-tests, as were histochemical studies with comparisons between two groups.  
 
For part 2. As repeated measurement ANOVA for the LDF recordings 
revealed significant group x time interaction effects, oneway ANOVA were computed 
for various time points, for which in case of significance, least significant difference 
(LSD) tests were calculated as post-hoc tests. Infarct volume, capillary density, IgG 
extravasation, MMP-9 activity and pericyte coverage were evaluated by oneway 
ANOVA followed by LSD tests. Three-way were also computed, from which 
significant interaction effects are reported in the text. Regional CBF, the metabolic 
penumbra and the area exhibiting ATP depletion were evaluated by oneway ANOVA 
followed by LSD tests. Two-way ANOVA were also calculated, from which significant 
interaction effects are presented. All data are presented as means ± SD. P≤ 0.05 was 
considered significant.  
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4 Results 
4.1 Effect of VEGF on brain angiogenesis, cerebral hemodynamics and tissue 
injury 
 
4.1.1 VEGF increases capillary density in a time dependant manner 
 
To assess how the i.c.v. delivery of VEGF influences microvascular networks 
in a time-dependent manner, capillary densities were analyzed by CD31 
immunohistochemistry. In comparison with vehicle treated animals, VEGF 
significantly increased capillary density from the 10th day post treatment in the 
ischemic hemisphere (Fig. 5A), where VEGF was applied and which for this reason 
was expected to exhibit the highest VEGF tissue concentrations. The effect persisted 
for up to 21 days after initiation of VEGF treatment (Fig. 5A). Two-way ANOVA 
revealed significant VEGF (F1,30=25.116; p< 0.001) and VEGF x treatment duration 
interaction (F2,30=3.426; p< 0.05) effects. In the contralateral hemisphere, at distance 
to the VEGF infusions, capillary density did not differ between groups (Fig. 5B). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. VEGF enhances cerebral capillary formation. CD31 
immunohistochemisty showing increased brain capillary densities starting 10 days 
after initiation of VEGF treatment (A) in the ischemic hemisphere of animals, to which 
VEGF was delivered, but not (B) the contralateral non-ischemic hemisphere at 
distance to the infusion site. Representative photographs from animals treated with 
vehicle or VEGF for 21 days are shown. Data are means ± SD (n=6-7 animals/ 
group). *p< 0.05/ **p< 0.01 compared with vehicle. Bar, 100 µm. 
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4.1.2 VEGF induces neuroprotection after ischemia 
 
To study the influence of VEGF on histological signs of brain injury after focal 
cerebral ischemia, mice were exposed to 90 min MCA occlusion. LDF recordings 
taken during and after MCA occlusion to control the reproducibility of ischemias did 
not reveal any differences between groups (Fig. 6A). Upon MCA occlusion, LDF 
decreased to 10-20% of baseline values in all groups. Reperfusion was associated 
with a rapid restoration of blood flow. 
 Infarct measurements on cresyl violet staining 24 hours after reperfusion 
revealed reduced infarct volumes in animals treated with VEGF for 10 or 21, but not 
for 3 days (Fig. 6B). Two-way ANOVA demonstrated robust effects of VEGF on 
infarct volume (F1,30=9.846; p< 0.01).  
 
   
 
 
 
 
 
 
 
 
 
 
Figure 6. VEGF attenuates brain injury following subsequent focal cerebral 
ischemia. Laser Doppler flow recordings during and after 90 minutes MCA 
occlusion. Note the reproducibility of MCA occlusions and reperfusions. No 
differences between groups were found (Fig 6A). Infarct volumes exhibiting reduction 
of ischemic injury after VEGF treatment for 10 or 21, but not 3 days (Fig 6B). 
Representative photographs from animals treated with vehicle or VEGF for 21 days 
are shown. Data are means ± SD (n=6-7 animals/ group). *p< 0.05/ **p< 0.01 
compared with vehicle. Bar, 100 µm. 
 
 
A B 
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4.1.3 Long term VEGF treatment preserves BBB integrity 
 
 
The attenuation of brain injury was associated with reduced IgG extravasation 
in animals receiving VEGF for 21, but not for 3 or 10 days (Fig. 7), demonstrating the 
formation of intact vessels are not associated with blood-brain barrier leakage. Two-
way ANOVA demonstrated robust effects of VEGF on IgG extravasation (F1,30=5.028; 
p< 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. VEGF reduces post-ischemic serum IgG extravasation. IgG 
immunohistochemistry demonstrating reduced IgG extravasation after VEGF 
treatment for 21, but not 3 or 10 days. Representative photographs from animals 
treated with vehicle or VEGF for 21 days are shown. Data are means ± SD (n=6-7 
animals/ group). *p< 0.05/ **p< 0.01 compared with vehicle. 
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4.1.4 VEGF reduces extracellular matrix disaggregation and ICAM1 expression 
 
To assess how VEGF influences extracellular matrix integrity and 
neuroinflammation, MMP-9 activity and ICAM-1 expression were analyzed by gelatin 
zymography and Western blots, respectively. Reduced MMP-9 activity was noted in 
ischemic tissues of animals receiving VEGF treatment for all treatment durations 
examined (Fig. 8 A), thus demonstrating that VEGF-induced angiogenesis is not 
achieved at the expense of excessive extracellular matrix breakdown. Two-way 
ANOVA revealed an effect of VEGF on MMP-9 activity (F1,18=40.185; p< 0.001). 
ICAM-1 expression in whole-brain lysates was transiently reduced by VEGF at 10 
days post treatment (Fig. 8 B). Two way ANOVA revealed a significant effect of VEGF 
on ICAM-1 (F1,24=4.517; p< 0.05). 
 
 
 
 
 
 
 
 
 
 
Figure 8. VEGF reduces MMP-9 activity and ICAM-1 expression in the ischemic 
brain. (A) Gelatin zymography showing decreased MMP-9 activity after 3, 10 and 21 
days of VEGF treatment, demonstrating that VEGF-induced angiogenesis is not 
achieved at the expense of increased extracellular matrix breakdown. (B) Western 
blots showing reduced ICAM-1 expression after 10 days of VEGF delivery, revealing 
an anti-inflammatory effect. Data are means ± SD (n=≥3 independent zymographies 
or blots. *p< 0.05/ **p< 0.01 compared with vehicle. 
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4.1.5 Rac1 activity is increased after VEGF treatment 
 
The RhoGTPase Rac1 induces endothelial motility and proliferation, actin 
cytoskeleton polymerization and endothelial barrier formation (Sawada et al., 2008), 
and can thus be used as a marker of angiogenesis. Rac1 G-LISA revealed that 
whereas no change in Rac1 activity was found in capillary extracts of animals treated 
with VEGF for 3 or 10 days, increased Rac1 activity was observed in ischemic 
tissues exposed to VEGF for 21 days (Fig. 9). Two-way ANOVA revealed a VEGF x 
treatment duration interaction effect for Rac1 activity (F2,32=4.506; p< 0.05). 
 
 
 
 
 
 
 
 
 
 
Figure 9. VEGF increases Rac1 activity in the ischemic brain. Rac1 G-LISA 
demonstrating increased Rac1 activity after 21 days of VEGF treatment, reflecting 
the maturation of functional vascular networks. Data are means ± SD (n=6-7 animals/ 
group). *p< 0.05/ **p< 0.01 compared with vehicle. 
 
In view of the fact that VEGF treatment for 21 days promoted angiogenesis 
while simultaneously enhancing blood-brain barrier and cell matrix integrity, we 
further evaluated the effects of VEGF-induced angiogenesis on regional CBF and 
brain metabolism in mice prophylactically treated with VEGF for 21 days.  
 
                                        VEGF-induced angiogenesis in focal cerebral ischemia/ 52 
 
4.1.6 VEGF increases regional CBF in the ischemic cortex and striatum 
 
The effects of VEGF-induced angiogenesis on brain hemodynamics were 
investigated by analysis of autoradiographic measurements of CBF. Increased 
regional CBF were noted in the ischemic cortex and striatum of VEGF compared with 
vehicle treated animals (Fig. 10 A), demonstrating that new vessel formation did 
indeed translate into a functional improvement of blood flow. Interestingly, increased 
CBF values were also observed in the contralateral non-ischemic striatum (Fig. 10 
B), albeit capillary density was not increased by VEGF treatment suggesting that 
mechanisms other than capillary density contributed to changes in CBF. 
 
 
  
 
 
 
 
 
 
Figure 10 (for legend see page 53) 
 
A B 
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Figure 10. VEGF increases regional CBF after focal cerebral ischemia (A) CBF 
analysis in the ischemic cortex and striatum of mice subjected to 90 min MCA 
occlusion showing improvement of blood flow 21 days after initiation of VEGF 
treatment. (B) CBF analysis in the contralateral hemisphere revealing increased 
blood flow in the striatum but not in cortex after 21 days of VEGF delivery. 
Representative images are also shown (top). Data are means ± SD (n=6 animals/ 
group). *p< 0.05/ **p< 0.01 compared with vehicle.  
 
4.1.7 VEGF-induced angiogenesis stabilizes the metabolic penumbra and 
prevents ATP depletion 
 
To evaluate how the improvement of regional CBF influences regional cerebral 
energy states, CPS and ATP bioluminescence images were assessed. A stabilization 
of the metabolic penumbra, defined as brain tissue in which CPS is suppressed but 
ATP preserved (Fig. 11 A), as well as a reduction in the area of tissue exhibiting ATP 
depletion (Fig. 11 B) was found in VEGF but not in vehicle treated animals, thus 
indicating that blood flow changes resulted in a preservation of energy metabolism.  
 
 
 
 
 
 
 
 
Figure 11. VEGF stabilizes the metabolic penumbra and prevents ATP 
depletion. (A) Preservation of the metabolic penumbra, defined as brain tissue in 
which CPS is suppressed but ATP preserved, due to VEGF-induced angiogenesis in 
animals after 21 days of VEGF delivery. (B) Reduction of ATP-depleted tissue in the 
same animals. Data are means ± SD (n=6 animals/ group). *p< 0.05/ **p< 0.01 
compared with vehicle.  
 
 
4.1.8 VEGF increases pericyte coverage of brain capillaries 
B A 
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To examine the functionality of cerebral blood vessels, pericyte coverage was 
analyzed. In the contralateral non-ischemic hemisphere, the vast majority of 
capillaries (~90%) were surrounded by pericytes (Fig. 12 B). In the ischemic tissue, 
this value was lower (~60%) in vehicle treated mice (Fig. 12 A). Interestingly, VEGF 
treatment did not affect the percentage of pericyte positive capillaries, when initiated 
3 or 10 days prior to stroke, but markedly increased pericyte coverage of ischemic 
capillaries, when started 21 days before (Fig. 12 A), indicating that VEGF induces the 
formation of mature vessels. Two-way ANOVA revealed a significant effect of VEGF 
(F1,30=8.981; p< 0.01) and a VEGF x treatment duration interaction effect for the 
percentage of pericyte covered vessels (F2,30=3.709; p< 0.05).  
 
 
 
 In view of the ceiling effect of pericyte coverage in the contralateral non-
ischemic tissue (Fig. 13B), where an increase in CBF, but not capillary density was 
found (see Figs. 5 and 10), a confocal data analysis was also performed, in which 
pericyte volumes determined in 3D stacks were related to the volumes of CD31+ 
cerebral capillaries. In this analysis, VEGF increased pericyte coverage in both 
hemispheres, when initiated 21 days before the stroke (Fig. 12 C, D). These data 
explained why VEGF increased CBF in the contralateral non-ischemic brain tissue 
although no increase in capillary density was seen. Two-way ANOVA revealed a 
VEGF x treatment duration interaction effect for the volume ratio (F2,29=3.447; p< 
0.05). 
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Figure 12. VEGF promotes pericyte coverage of brain endothelial cells. (A, B) 
Percentage of pericyte positive microvessels in the ischemic and contralesional non-
ischemic brain tissue, (C, D) volume coverage of microvessels by pericytes, 
Representative microphotographs from animals treated with vehicle or VEGF for 21 
days are also shown (CD31 in A and B in green/ desmin in A and B in red). Data are 
means ± SD (n=6-7 animals/ group). *p< 0.05/ **p< 0.01 compared with vehicle. Bar, 
100 µm. 
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4.1.9 VEGF increases the junctional protein N-cadherin on cerebral 
microvessels 
 
The alignment of pericytes to endothelial cells is mediated by the junctional 
protein N-cadherin (Winkler et al., 2011). To evaluate whether N-cadherin was 
influenced by VEGF, Western blots were prepared with capillary extracts which 
revealed increased N-cadherin expression in microvessels that had been harvested 
21 days after the initiation of VEGF treatment (Fig.13).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. VEGF increases the expression of the junctional protein N-cadherin 
on cerebral microvessels. N-cadherin expression on cerebral microvessels in 
animals treated with VEGF for 21 days. Representative blots from animals treated 
with vehicle or VEGF for 21 days are also shown. Data are means ± SD (n=4 
independent blots). *p< 0.05/ **p< 0.01 compared with vehicle.  
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4.1.10 VEGF does not influence apoptotic death of pericytes 
 
To rule out whether changes in pericyte coverage in the ischemic tissue were 
partly due to reduced pericyte death, numbers of desmin/ TUNEL and desmin/ 
cleaved caspase-3 double positive pericytes were analyzed. Notably, VEGF 
treatment neither influenced deoxyribonucleic acid (DNA) fragmentation nor caspase-
3 activation (Fig. 14). 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 14. VEGF does not influence pericytic injury. DNA-fragmented (i.e., 
TUNEL+) and apoptotic (i.e., cleaved caspase-3+) pericytes, evaluated using the 
pericyte marker desmin in animals treated with VEGF for 21 days. Note the absence 
of effects of VEGF on pericyte injury. Representative microphotographs from animals 
treated with vehicle or VEGF for 21 days are also shown (TUNEL and cleaved 
caspase-3 in green/ desmin in red). Data are means ± SD (n=6-7 animals/ group). 
*p< 0.05/ **p< 0.01 compared with vehicle. Bar, 40 µm.  
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4.1.11 VEGFR2 and VEGFR1 are not expressed on mouse brain pericytes 
 
Since VEGF has previously been shown to induce pericyte ablation in Matrigel 
assays, which was interpreted as consequence of VEGFR2/ PDGFRβ interaction on 
pericytes (Greenberg et al., 2008), the question arose whether pericytes in the 
C57BL6/j mouse strain we used expressed VEGFR2 or VEGFR1. In 
immunostainings, we were unable to detect VEGFR2 and VEGFR1 on pericytes (Fig. 
15 A, B). 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Absence of VEGFR2 and VEGFR1 on pericytes. Immunofluorescence 
photographs revealing VEGFR2 (A) and VEGFR1 (B) (both in green) on ischemic 
endothelial cells (in case of VEGFR2 in A) or parenchymal cells (in case of VEGFR1 
in B), but not on pericytes (in red). Bar, 20 µm.  
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4.2 Effect of hyperlipidemia on VEGF-induced angiogenesis 
 
4.2.1 VEGF-induced capillary formation is blunted by hyperlipidemia 
 
To examine how the i.c.v. delivery of VEGF influences microvascular networks 
in wildtype and ApoE-/- mice, brain capillary density was analysed by CD31 
immunohistochemistry. VEGF increased capillary density in wildtype mice on normal 
diet and Western diet and ApoE-/- mice on normal diet, but not in ApoE-/- mice on 
Western diet (Fig.16 A,B). Three-way ANOVA showed a significant interaction effect 
for VEGF x ApoE x dietary status on capillary density (F1,39=4.444; p<0.05), 
demonstrating that angiogenesis was prevented by hyperlipidemia, most strongly in 
animals exhibiting the highest cholesterol levels (i.e., ApoE-/- mice on Western diet).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Hyperlipidemia prevents VEGF-induced brain capillary formation. (A, 
B) CD31 immunohistochemisty showing an increased capillary density in VEGF 
treated wildtype mice kept on normal and Western diet and ApoE-/- mice on normal 
diet. Capillary formation is blunted in ApoE-/- mice on Western diet that exhibit the 
highest plasma cholesterol levels between all groups. Representative 
microphotographs from wildtype mice kept on normal diet and ApoE-/- mice on 
Western diet are also shown. Data are means±SD (n=6-7 animals/ group). *p<0.05/ 
**p<0.01 compared with corresponding vehicle. Bar, 100 µm. 
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4.2.2 Hyperlipidemia induces post-ischemic hypoperfusion  
 
To evaluate the effects of hyperlipidemia on histopathological brain injury and 
blood-brain barrier integrity, mice treated with vehicle or VEGF were exposed to 90 
min MCA occlusion followed by 24 hours reperfusion. LDF recordings taken during 
and after MCA occlusion revealed reproducible ischemic impacts that did not differ 
between vehicle and VEGF treated mice (Fig.17 A,B). Post-ischemic LDF values 
were lower in animals on Western diet than animals on normal diet (Fig.17 A,B).  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Hyperlipidemia induces post-ischemic hypoperfusion. LDF 
recordings confirming the reproducibility of MCA occlusions. Note that LDF values 
after reperfusion are lower in animals kept on Western diet than in animals kept on 
normal diet. Data are means ± SD (n=6-7 animals/ group). *p<0.05 for VEGF treated 
normal diet compared with vehicle treated normal diet; †p<0.05 for vehicle treated 
Western diet compared with vehicle treated normal diet. 
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4.2.2 Hyperlipidemia abolishes VEGF-induced neuroprotection 
 
Infarct measurements on cresyl violet stainings at 24 hours after reperfusion 
revealed that VEGF reduced infarct volume in wildtype mice kept on normal diet 
(Fig.19A), which is in line with earlier results of our group (Wang et al., 2005; 
Zechariah et al., 2011). Conversely, VEGF did not influence infarct size in wildtype 
mice on Western diet, ApoE-/- mice on normal diet or ApoE-/- mice on Western diet 
(Fig.18 A,B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Hyperlipidemia abolishes VEGF-induced neuroprotection. (A, B) 
Infarct volume of mice submitted to 90 minutes MCA occlusion followed by 24 hours 
reperfusion showing VEGF-induced reduction of ischemic injury in wildtype mice on 
normal diet, but not in wildtype mice on Western diet and in ApoE-/- mice on normal 
or Western diet that exhibit hyperlipidemia. Representative images from wildtype 
mice kept on normal diet and ApoE-/- mice on Western diet are also shown. Data are 
means ± SD (n=6-7 animals/ group). *p<0.05/ **p<0.01 compared with corresponding 
vehicle.  
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4.2.3 Hyperlipidemia abolishes VEGF-induced preservation of blood-brain 
barrier integrity 
 
Serum IgG extravasation evaluated using immunohistochemistry revealed the 
status of BBB under conditions of hypercholestremia. The attenuation of brain injury 
in wildtype mice on normal diet was also associated with reduced IgG extravasation. 
The preservation of BBB induced by VEGF was abolished under conditions of 
hyperlipidemia leading to increased extravasation of serum proteins (Fig.19 A,B). 
 
 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Hyperlipidemia abolishes VEGF-induced blood-brain barrier 
preservation. (A, B) Immunohistochemistry aganist serum IgG, demonstrating 
decreased serum IgG extravasation by VEGF in wildtype mice on normal diet, but not 
in wildtype mice on Western diet and ApoE-/- mice on normal or Western diet. In 
these animals, tissue samples derived from the ischemic MCA territory (striatum and 
overlying cortex) were analysed. Representative images from wildtype mice kept on 
normal diet and ApoE-/- mice on Western diet are also shown. Data are means ± SD 
(n=6-7 animals/ group). *p<0.05/ **p<0.01 compared with corresponding vehicle.  
 
 
 
A B 
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4.2.4 Hyperlipidemia prevents VEGF-induced extracellular matrix preservation 
 
To assess how hyperlipidemia influences extracellular matrix integrity after 
VEGF treatment, MMP-9 activity was analysed by gelatin zymography. In line with a 
previous study (Reitmeier et al., 2012), VEGF reduced MMP-9 activity both in 
ischemic tissue samples obtained from wildtype and ApoE-/- mice, yet more strongly 
in animals kept on normal diet than on Western diet (Fig.20 A,B), indicating that 
hyperlipidemia promoted extracellular matrix breakdown. Indeed, VEGF treated 
ApoE-/- mice on Western diet exhibited significantly higher MMP-9 activity than ApoE-
/-
 mice on normal diet (Fig.20 B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Hyperlipidemia abolishes VEGF-induced extracellular matrix 
preservation. (A, B) Gelatin zymography exhibiting deactivation of MMP-9 by VEGF 
in wildtype mice on normal diet that is attenuated in wildtype mice on Western diet 
and ApoE-/- mice on normal or Western diet. Tissue samples derived from the 
ischemic MCA territory (striatum and overlying cortex) were analysed. Representative 
images from wildtype mice kept on normal diet and ApoE-/- mice on Western diet are 
also shown. Data are means ± SD (n=6-7 animals/ group). *p<0.05/ **p<0.01 
compared with corresponding vehicle. ††p<0.01 compared with corresponding normal 
diet.  
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4.2.5 Hyperlipidemia attenuates VEGF-induced improvement of regional CBF 
  
To elucidate the effect of VEGF-induced angiogenesis on brain hemodynamics 
during a subsequent stroke, CBF autoradiograms were analysed at 60 min after MCA 
occlusion. Increased regional CBF was noted in the MCA territory of VEGF treated 
wildtype mice on normal diet but not in VEGF treated ApoE-/- mice on Western diet 
(Fig.21 A), indicating a lack of functional hemodynamic improvements in animals with 
hyperlipidemia. Two-way ANOVA demonstrated a significant effect of VEGF 
(F1,20=8,705; p<0.01), but no interaction effect with ApoE/ dietary status on regional 
CBF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 (for legend see page 65) 
                                        VEGF-induced angiogenesis in focal cerebral ischemia/ 65 
 
Figure 21. Hyperlipidemia abolishes VEGF-induced improvement of cerebral 
blood flow. (A) Regional CBF autoradiography showing increased blood flow values 
in ischemic brain tissue of VEGF treated wildtype mice on normal diet that are 
attenuated in ApoE-/- mice on Western diet that exhibit hyperlipidemia. Animals were 
exposed to 90 minutes MCA occlusion, followed by 60 minutes reperfusion. Tissue 
samples derived from the ischemic MCA territory (striatum and overlying cortex) were 
evaluated. Representative autoradiographies and bioluminescence images are also 
shown. Data are means ± SD (n=6 animals/ group). *p<0.05/ **p<0.01 compared with 
corresponding vehicle.  
 
4.2.6 Hyperlipidemia abolishes VEGF-induced stabilization of metabolic 
penumbra 
 
To evaluate how the improvement of regional CBF influences regional cerebral 
energy state, CPS and ATP bioluminescence images were assessed. A stabilization 
of the metabolic penumbra, defined as brain tissue in which CPS was suppressed but 
ATP preserved, was noticed in VEGF treated wildtype mice on normal diet but not in 
ApoE-/- mice on Western diet (Fig.22 A). Two-way ANOVA showed a significant VEGF 
x ApoE/ dietary status interaction effect (F1,14=4.663; p<0.05), indicating that 
hyperlipidemia promotes secondary brain infarction. Indeed, the tissue area 
exhibiting ATP depletion after 60 minutes of reperfusion was considerably smaller in 
normolipidemic wildtype than hyperlipidemic ApoE-/- mice (Fig.22 B), although this 
difference still failed to show significance at this time point.  
 
 
 
 
 
 
 
 
 
 
Figure 22 (for legend see page 66) 
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Figure 22. Hyperlipidemia abolishes VEGF-induced preservation of brain 
energy state. (A) Metabolic penumbra, defined as tissue area in which cerebral 
protein synthesis is suppressed, but ATP preserved, exhibiting the viability of the 
metabolic penumbra as a result of the enhanced blood flow in VEGF treated wildtype 
mice on normal diet, but not in hyperlipidemic ApoE-/- mice on Western diet. (B) 
Tissue area exhibiting ATP depletion, revealing reduced breakdown of the cerebral 
energy state in VEGF treated normolipidemic wildtype mice, but not in hyperlipidemic 
ApoE-/- mice. Animals were exposed to 90 minutes MCA occlusion, followed by 60 
minutes reperfusion. Tissue samples derived from the ischemic MCA territory 
(striatum and overlying cortex) were evaluated. Data are means ± SD (n=6 animals/ 
group). *p<0.05/ **p<0.01 compared with corresponding vehicle.  
 
 
4.2.7 Hyperlipidemia prevents VEGF-induced pericyte alignment on brain 
capillaries 
 
To examine the functionality of cerebral blood vessels in addition to structural 
growth, pericyte coverage was analysed in brain tissue samples submitted to focal 
cerebral ischemia. In the ischemic tissue, the percentage of cerebral microvessels 
surrounded by pericytes was around 60% in 20 µm thick cryostat sections (Fig.24 
A,B). Interestingly, VEGF treatment increased the percentage of pericyte+ capillaries 
in wildtype mice on normal diet (relatively by ~30%), but not in wildtype mice on 
Western diet or ApoE-/- mice on normal or Western diet (Fig.23 A,B). Three-way 
ANOVA revealed a significant VEGF x ApoE x dietary status interaction effect 
(F1,41=4.487; p<0.05).  
 
 To further corroborate these findings, we subsequently performed a confocal 
data analysis, in which pericyte volumes determined in 3D stacks were related to 
volumes of CD31+ cerebral capillaries. This study again revealed an increased 
pericyte coverage of brain endothelial cells in VEGF treated wildtype mice on normal 
diet, but not in wildtype mice on Western diet or any of the ApoE-/- mice (Fig.23 C,D). 
Three-way ANOVA again confirmed a VEGF x ApoE x dietary status interaction effect 
(F1,41=7,325; p<0.05), confirming that hyperlipidemia disturbed the alignment of 
pericytes with endothelial cells. 
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Figure 23. Hyperlipidemia prevents VEGF-induced pericyte alignment on brain 
capillaries. (A, B) Percentage of cerebral microvessels surrounded by pericytes in 
20 µm cryostat sections, (C, D) volume ratio of pericyte coverage of ischemic brain 
capillaries determined in 3D stacks. Note the increased pericyte coverage in VEGF 
treated wildtype mice on normal diet, but not in wildtype mice on Western diet or in 
ApoE-/- mice on normal or Western diet that exhibit hyperlipidemia (A-D). Animals 
were submitted to 90 minutes MCA occlusion followed by 24 hours reperfusion. 
Tissue samples derived from the ischemic MCA territory (striatum and overlying 
cortex) were evaluated. Representative microphotographs are also shown (CD31 in 
green/ desmin in red). Data are means±SD (n=6-7 animals/ group). *p<0.05/ 
**p<0.01 compared with vehicle. Bar, 100 µm. 
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4.2.8 Hyperlipidemia attenuates N-cadherin expression in cerebral 
microvessels 
 
The physical interaction of pericytes with endothelial cells is mediated by the 
junctional protein N-cadherin (Winkler et al., 2011). To evaluate whether N-cadherin 
expression was altered by an increase in blood lipids, Western blots were prepared 
with capillary extracts obtained from normolipidemic and hyperlipidemic wildtype and 
ApoE-/- mice. This study revealed that VEGF potently increased N-cadherin levels in 
ischemic microvessels obtained from wildtype mice on normal diet, but not in any of 
the hyperlipidemic groups (Fig.24 A,B). The lack of N-cadherin expression provides a 
mechanism for the disturbed pericyte coverage of endothelial cells in hyperlipidemia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Hyperlipidemia decreses N-cadherin expression affecting pericyte 
alignment on brain capillaries. (A, B) N-cadherin expression in ischemic cerebral 
microvessels of wildtype and ApoE-/- mice on normal or Western diet. Also note the 
increased expression of N-cadherin, which physically links the pericytes with 
endothelial cells, in VEGF treated wildtype mice on normal diet, but not in 
hyperlipidemic wildtype mice on Western diet or ApoE-/- mice. Animals were 
submitted to 90 minutes MCA occlusion followed by 24 hours reperfusion. 
Microvessels derived from the ischemic MCA territory (striatum and overlying cortex) 
were evaluated. Representative blots are also shown. Data are means±SD (n=4 
independently processed blots). *p<0.05/ **p<0.01 compared with vehicle.  
A B 
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5 Discussion 
 
Understanding the pathophysiological mechanisms involved in the innate 
recovery process of the brain is crucial for developing therapeutic strategies. 
Angiogenesis is a crucial component of the neurovascular remodeling occurring after 
cerebral ischemia. Assessing the role of major risk factors such as atherosclerosis on 
remodeling promoting strategies is decisive for minimising translational failures.  
 
By using a multiparametric approach in wildtype animals we show that VEGF 
induces the formation of new vessels leading to increase in cerebral perfusion and 
preservation of the cerebral energy state after focal cerebral ischemia. Our results 
also demonstrated increased pericyte coverage of cerebral capillaries after VEGF 
treatment by augmenting N-cadherin expression. Our observations demonstrated the 
ability of VEGF to induce neurovascular remodelling; even though the application 
strategies and compromising effects of risk factors still needs to be optimised and 
investigated. 
 
By utilising hyperlipidemic wildtype and ApoE-/- animals we furthermore 
demonstrate that VEGF induced new vessel formation is compromised under 
conditions of hyperlipidemia. Dysfunctional angiogenesis was followed by decreased 
cerebral perfusion and less preservation of the cerebral energy state. Additionally, 
hyperlipidemia affected pericyte coverage of brain vessels by decreasing N-cadherin 
expression. Our observations clearly demonstrate the shortcomings of translational 
studies in ischemic stroke which utilise normolipidemic, healthy animals which do not 
reflect the pathophysiology encountered in clinical situations. 
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5.1 VEGF promotes pericyte coverage of brain capillaries, improves cerebral 
blood flow during subsequent focal cerebral ischemia, and preserves the 
metabolic penumbra  
 
By applying prophylactic VEGF for up to 21 days, we have shown that VEGF 
induces the formation of mature, functional blood vessels, which enables the brain to 
better cope with subsequent ischemic episodes, thus enhancing regional CBF, 
stabilizing cerebral energy state and preventing brain infarction. In our study, 
increased brain capillary densities were noted within 10 days of initiation of VEGF 
treatment, which were accompanied by enhanced pericyte coverage of endothelial 
cells within 21 days. The induction of angiogenesis closely paralleled tissue survival, 
providing evidence of links between new vessel formation, hemodynamic changes 
and tissue preservation.  
 
Previous investigations have demonstrated the ability of VEGF to stimulate the 
production of capillaries in intact brain (Zhao et al., 2010; Yano et al., 2005; Wang et 
al., 2005) and after focal cerebral ischemia (Reitmeir et al., 2012; Wang et al., 2007c; 
Sun et al., 2003). In our study VEGF delivery increased the number of new born 
vessels after 10 and 21 days but not after 3 days of treatment which is line with 
previous reports revealing that increase of new vessels in the brain starts only 
around 48 hours after stroke (Seylaz et al., 1999; Marti et al., 2000; Pinard et al., 
2000). Additionally, by utilising autoradiographic techniques we now were able to 
show that selective induction of vessels by chronic treatment with VEGF leading to 
the increase in CBF and to the preservation of the cerebral energy state after focal 
cerebral ischemia.  
 
 Our observation that induced angiogenesis increases blood flow in the 
ischemic brain contrasts with earlier findings of our own group using a transgenic 
mouse line expressing human VEGF under control of a neuron-specific NSE 
promoter (Wang et al., 2005). In that mouse line, increased regional CBF, evaluated 
using 4-iodo-N-methyl-[14C] antipyrine, was described only in non-ischemic brain 
areas outside the MCA territory, while regional CBF within the ischemic MCA territory 
was actually reduced (Wang et al., 2005). These data were interpreted as an 
indication of a hemodynamic steal flow phenomenon induced by enhanced 
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angiogenesis (Wang et al., 2005). Indeed, human VEGF-transgenic mice exhibited 
an increased brain capillary density throughout the brain, which might explain why 
blood flow was redirected into non-ischemic areas. While capillary density was 
increased by up to 100% or even more in human VEGF-transgenic mice, only mildly 
increased blood flow values were noted in this mouse line under physiological 
conditions during hypercapnia (Vogel et al., 2004). These findings raised doubts 
whether microvascular networks are adopted to tissue needs in this mouse line. In a 
magnetic resonance imaging study, acute VEGF infusion was previously shown to 
induce transient CBF increases in ischemic brain tissue lasting up to 3 hours (Zhang 
et al., 2000), which however was a consequence of VEGF-induced vasorelaxation 
rather than of induced vascular growth. 
 
 
 The capability of blood vessels to respond to tissue needs depends on proper 
interactions between endothelial cells with pericytes (Kaya et al., 2005), which, as we 
show, are enhanced by VEGF treatment. The increased pericyte coverage of brain 
capillaries was associated with an enhanced expression of the junctional protein N-
cadherin. N-cadherin promotes the alignment of pericytes to endothelial cells by 
enabling direct physical interactions between both cell types (Kaya et al., 2005). Our 
observation of increased pericyte coverage indicates that therapeutic angiogenesis 
may have beneficial effects beyond elevating capillary density. In our study we 
observed an enhanced pericyte coverage following VEGF treatment also in areas not 
exhibiting vascular sprouting. Notably in the contralateral striatum, at distance to the 
VEGF infusion, potently increased CBF values were noticed despite lack of 
angiogenesis, which is well explained by the recruitment of pericytes. Our results are 
in contrast to observations following VEGF treatment in a model of PDGF-BB-
induced angiogenesis, where a loss of pericyte coverage was reported, which was 
mediated by the deactivation of PDGFRβ by VEGFR2 (Greenberg et al., 2008). In 
the present study, we have not been able to detect VEGFR2 on brain pericytes, 
neither under physiological conditions nor following stroke. Differences of the growth 
factors used –combined VEGF/PDGF-BB delivery vs. VEGF delivery only– together 
with differences in the experimental systems – Matrigel assay vs. focal cerebral 
ischemia– may explain diverging results.  
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In addition to increased new vessel formation and perfusion, chronic VEGF 
delivery for 10 and 21 days also reduced tissue injury after focal cerebral ischemia. 
Our results are in line with previous observations where reductions in infarct volume 
(Li et al., 2009; Wang et al., 2007c; Shen et al., 2006; Kaya et al 2005; Sun et al., 
2003; Hayashi et al., 1998; Emerich et al., 2010), reduced secondary neuronal 
degeneration (Herz et al., 2012), DNA fragmented cells (Shen et al., 2006), TUNEL 
positive cells (Kaya et al., 2005) and reduction in cell shrinkage and DNA cleavage 
(Sun et al., 2003) were observed after local delivery of VEGF. The ability of VEGF to 
influence tissue injury could be explained by the presence of functional newborn 
vessels facilitating increased perfusion of tissue and the reduction of infarct volume 
after focal cerebral ischemia.  
 
A major concern regarding VEGF-induced angiogenesis is the increased BBB 
permeability that is more pronounced following acute (Zhang et al., 2000; Kaya et al., 
2005) than prophylactic (Wang et al., 2005; Bellomo et al., 2003) or post-acute 
(Zhang et al., 2000) VEGF delivery, and more pronounced after intravenous (Zhang 
et al., 2000; Kaya et al., 2005) than local brain (Wang et al., 2005; Bellomo et al., 
2003) administration. VEGF pre-treatment for 6-12 days have been shown to 
decrease brain edema in gerbils (Bellomo et al., 2003) while increased BBB damage 
was observed when delivered during the acute phase after stroke (Zhang et al., 
2000) in rats. Furthermore, VEGF antagonisation during the acute phase of stroke 
resulted in decreased edema formation (van Bruggen et al., 1999).  Additionally, local 
delivery of VEGF, 1-3 days after stroke, was observed to reduce infarct size, improve 
neurological performance, enhance delayed survival of newborn neurons and to 
stimulated angiogenesis after focal cerebral ischemia in rats (Sun et al., 2003). In our 
study, the extravasation of serum IgG was markedly reduced in animals with 21 days 
of VEGF treatment but not after 3 or 10 days. Even though the number of new born 
vessels was increased after 10 days of treatment, pericyte coverage was only 
increased after 21 days of VEGF treatment which explains the reduction in IgG 
extravasation in these animals owing to better preservation of BBB by enhanced 
pericyte coverage. These data reveal that the duration of VEGF exposure critically 
influences the integrity of newly formed vessels.  
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Using MMP-9 gelatin zymography and protein expression analysis we show 
that long term VEGF treatment diminishes MMP-9 activity and transiently reduces 
inflammation after focal ischemia. MMP-9 activation is often linked to changes in the 
BBB by disrupting the cell matrix interactions leading to brain swelling and 
intracerebral haemorrhage (Wang et al., 2003; Cheng et al., 2006; Burggraf et al., 
2007). Selective MMP inhibition leads to decreased brain injury, brain swelling, BBB 
breakdown and better functional outcome after focal cerebral ischemia in rats (Nagel 
et al., 2011). Specific MMP-9 inhibition alleviated BBB disruption, decreased brain 
edema and inhibited the production of inflammatory cytokines after cardiopulmonary 
resuscitation in rats (He et al., 2009). A recent investigation have demonstrated that 
post-acute delivery of VEGF attenuated CD45+ leukocyte infiltrates and diminished 
the microglial activation by downregulation of a board set of inflammatory cytokines 
and chemokines (Herz et al., 2012). The action of VEGF on BBB breakdown has 
been shown to depend on the route and time point of delivery (Hermann and 
Zechariah, 2009). According to our study, prophylactic local delivery of VEGF leads 
to preservation of BBB integrity and to the decrease in inflammation after focal 
cerebral ischemia.  
 
Long term VEGF treatment increased Rac1 activity in our study, which is 
known to mediate endothelial cell motility, proliferation, survival, and endothelial 
barrier formation. Endothelial-specific Rac1 insufficient mice show impaired 
angiogenesis (Johanna et al., 2010). Rac1 activity is also involved in the 
degenerative process and long term recovery after cerebral ischemia (Sawada et al., 
2008). An inactive state of Rac1 was correlated with decreased survival signalling, 
significant tauopathy along with learning and memory alterations after global cerebral 
ischemia in rats; an effect which was reversed after normalization of Rac1 levels 
(Sawada et al., 2008). In our study, increase in Rac1 activity correlated with increase 
in new vessel formation and preservation of the BBB integrity, indicating that the 
survival promoting effects of VEGF, at least partially, was mediated through the Rac1 
GTPase pathway. As such, Rac1 GTPase pathway could be a specific target for 
future therapeutic interventions.  
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As we have evaluated therapeutic angiogenesis in hitherto healthy adolescent 
mice with intact vascular networks, the question remained whether the data obtained 
could be translated to the situation in mice with pre-existing atherosclerosis. Hence, 
in order to understand the effect of hyperlipidemia on therapeutic angiogenesis, we 
chose to compare normolipidemic wildtype animals treated with VEGF for 21 days 
(the group which showed robust increase in CBF, pericyte coverage and BBB 
integrity in the first part of our study) with hyperlipidemic wildtype and ApoE-/- 
animals. 
 
 
5.2 Hyperlipidemia attenuates VEGF-induced angiogenesis, impairs cerebral 
blood flow and disturbs stroke recovery via decreased pericyte coverage of 
brain endothelial cells 
 
 
Using a multiparametric approach combining histochemical, autoradiographic, 
bioluminescence and molecular biological studies we herein show that VEGF-
induced angiogenesis is compromised by hyperlipidemia, translating into the loss of 
hemodynamic improvements following subsequent stroke injuries, the breakdown of 
the metabolic penumbra and brain infarction. Furthermore, N-cadherin expression 
was reduced on cerebral microvascular cells exposed to hyperlipidemia that was 
associated with decreased coverage of endothelial cells with pericytes, 
demonstrating that blood vessels were dysfunctional. 
  
As ischemic stroke results from the gradual accumulation of many factors, the 
observed benefits of therapeutic angiogenesis in healthy animals could not be 
directly translated to the clinical setting. In order to address this issue, we now 
utilised wildtype and ApoE-/- mice fed with regular or cholesterol-rich chow to induce 
different degrees of hyperlipidemia. Our data might provide an explanation for the 
poor effects of angiogenic therapies in human patients with symptomatic 
atherosclerosis (Simons and Ware, 2003; Hermann and Zechariah, 2009; Potente et 
al., 2011). These patients frequently suffer from hyperlipidemia and particularly brain 
vessels are affected by atherosclerotic plaques (Turan et al., 2010; Park et al., 2011). 
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In our study, the ability of VEGF to induce new vessel formation was blunted 
under conditions of severe hyperlipidemia. Interestingly, new vessel formation was 
preserved in the mildly hyperlipidemic animals. Impaired spontaneous angiogenesis 
has previously been noted under conditions of hyperlipidemia (van Belle et al., 1997; 
Duan et al., 2000; Jang et al., 2000). Thus, reduced vessel densities have been 
reported in hyperlipidemic rats exposed to hindlimb ischemia, which was attributed to 
reduced nitric oxide activity in hyperlipidemic ischemic tissue (Duan et al., 2000). 
Consequences of hyperlipidemia on brain angiogenesis and on the responses of 
blood vessels to VEGF were so far unknown.  
 
In mice expressing human VEGF chronically in the whole brain under a 
neuron-specific NSE promoter, regional CBF was observed to be reduced in 
ischemic brain areas as a consequence of a hemodynamic steal flow (Wang et al., 
2005). However, the exogenous delivery of VEGF differs from transgenic VEGF 
expression, as it increases regional CBF in ischemic brain tissue (Zechariah et al., 
2011). Importantly, both the VEGF-induced angiogenesis and the enhancement of 
blood flow were blunted in animals exhibiting hyperlipidemia, leading to failure of the 
cerebral energy state after focal cerebral ischemia. The lack of CBF improvements 
under conditions of hyperlipidemia and after therapeutically induced angiogenesis, to 
the best of our knowledge, has never been described before.  
 
 Besides preventing the sprouting of cerebral microvessels, hyperlipidemia 
abolished the enhanced coverage of endothelial cells with pericytes. Pericytes exert 
an important regulatory role in brain microvessels, inducing the formation of blood-
brain barrier properties and controlling vascular reactivity (Winkler et al., 2011). In 
line with the disturbed pericyte coverage, the junctional protein N-cadherin which 
mediates physical interactions between endothelial cells and pericytes and which 
was upregulated by VEGF in normolipidemic microvessels, did not respond to VEGF 
in hyperlipidemic mice. An interesting aspect of our results is that VEGF treatment 
was able to increase new vessel formation in the mildly hyperlipidemic animals while 
on the other hand, was not able to increase the pericyte coverage of vessels in these 
animals. Additionally, the increased abundance of the junctional protein N-cadherin 
was lost, also in the mildly hyperlipidemic animals. That hyperlipidemia prevents the 
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pericyte alignment with endothelial cells is noteworthy. It provides a new, hitherto 
unknown mechanism for disturbances of vascular reactivity in hyperlipidemia.  
 
Indeed, the VEGF induced preservation of the BBB integrity was abolished 
under conditions hyperlipidemia, which was reflected by the enhanced access of 
serum IgG to the brain parenchyma. It is noteworthy that increased IgG extrasavation 
correlated with the decrease in pericyte coverage under conditions of hyperlipidemia. 
As pericyte coverage is crucial for maintaining a non-leaky BBB; hyperlipidemia, by 
counteracting pericyte contact with endothelial cells lead to the formation of leaky, 
dysfunctional vessels after angiogenesis therapy.  
  
A recent investigation has demonstrated that hyperlipidemia promotes BBB 
permeability after focal cerebral ischemia, thereby increasing brain edema by 
activation of MMP-2/9 and overactivation of RhoA (Elali A et al., 2011b). By 
investigating MMP-9 activity in hyperlipidemic animals, we now show that 
hyperlipidemia reverses the preservation of extracellular matrix integrity induced by 
VEGF; by increasing MMP-9 activity. Besides, MMP-9 activity in the severely 
hyperlipidemic animals was highly exacerbated, compared to the moderately 
hyperlipidemic animals, further demonstrating the role of hyperlipidemia on 
extracellular matrix integrity.  
 
Infarct volumetric analysis after focal cerebral ischemia demonstrated a 
hitherto unknown outcome that hyperlipidemia abolished the neuroprotective effect of 
VEGF resulting in increased infarction volumes. It could be explained by our 
observation that hyperlipidemia abolishes the improvement of blood flow induced by 
VEGF and also decreases pericyte coverage on vessels. Hence, the inability of 
vessels to respond to the metabolic demands of the tissue after ischemia, promoted 
the progression of brain injury.  
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6 CONCLUSIONS AND OUTLOOKS 
 
The reasons for the failure in translation of therapeutic strategies have been a 
topic of intense discussion recently. Utilisation of clinically irrelevant animal models 
and readouts may be attributable for these discrepancies. Translational stroke 
research poorly mimic comorbidities as experiments are done in young and healthy 
animals (Hermann and Chopp, 2012). 
 
 Experimental therapeutic angiogenic strategies often chose to look at readouts 
which are clinically less relevant and thereby largely ignoring the changes in 
perfusion which is the primary purpose of inducing angiogenesis. Our investigation 
on healthy animals revealed the efficacy of VEGF to induce vessel formation, 
resulting in increased CBF and preservation of the cerebral energy state. These data 
supported the concept of induced angiogenesis for hitherto healthy mice.  
 
Approximately, half of all stroke patients are hyperlipidemic. By utilising 
hyperlipidemic animals we showed that hyperlipidemia reverses the angiogenic 
responses induced by VEGF. Translational stroke studies should be aware that 
hyperlipidemia profoundly alters responses of cerebral blood vessels to angiogenic 
growth factors. The lack of vascular growth responses following VEGF treatment 
questions the concept of therapeutic angiogenesis in ischemic stroke.  
 
Our investigation utilising normolipidemic and hyperlipidemic animals has 
demonstrated the pitfalls that result from the use of inadequate animal models. Our 
results argue in favour of a paradigm shift in experimental strategies that more 
approximately consider vascular risk factors and thus more closely resemble clinical 
conditions. 
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